<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Phytomedicine</journal-id><journal-id journal-id-type="iso-abbrev">Phytomedicine</journal-id><journal-title-group><journal-title>Phytomedicine</journal-title></journal-title-group><issn pub-type="ppub">0944-7113</issn><issn pub-type="epub">1618-095X</issn><publisher><publisher-name>Elsevier GmbH.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7118492</article-id><article-id pub-id-type="publisher-id">S0944-7113(20)30041-6</article-id><article-id pub-id-type="doi">10.1016/j.phymed.2020.153208</article-id><article-id pub-id-type="publisher-id">153208</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Tang</surname><given-names>Bin</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Lo</surname><given-names>Hang Hong</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Lei</surname><given-names>Cheng</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>U</surname><given-names>Ka In</given-names></name><xref rid="aff0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Hsiao</surname><given-names>Wen-Luan Wendy</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Guo</surname><given-names>Xiaoling</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Bai</surname><given-names>Jun</given-names></name><xref rid="aff0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0008"><name><surname>Wong</surname><given-names>Vincent Kam-Wai</given-names></name><email>kawwong@must.edu.mo</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au0009"><name><surname>Law</surname><given-names>Betty Yuen-Kwan</given-names></name><email>lykbetty@gmail.com</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff0001"><label>a</label>State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China</aff><aff id="aff0002"><label>b</label>Department of Pediatrics, Kiang Wu Hospital, Macau SAR, China</aff><aff id="aff0003"><label>c</label>South Medical University Affiliated Maternal &#x00026; Child Health Hospital of Foshan, Foshan, China</aff><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding authors. <email>kawwong@must.edu.mo</email><email>lykbetty@gmail.com</email></corresp><fn id="fn1"><label>1</label><p id="notep0001">Equal contributors.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>3</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>15</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2020</year></pub-date><volume>70</volume><fpage>153208</fpage><lpage>153208</lpage><history><date date-type="received"><day>22</day><month>11</month><year>2019</year></date><date date-type="rev-recd"><day>17</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier GmbH. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier GmbH</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0001"><sec><title>Background</title><p>Kawasaki disease (KD) is a self-limiting acute systemic vasculitis occur mainly in infants and young children under 5 years old. Although the use of acetylsalicylic acid (AAS) in combination with intravenous immunoglobulin (IVIG) remains the standard therapy to KD, the etiology, genetic susceptibility genes and pathogenic factors of KD are still un-elucidated.</p></sec><sec><title>Purpose</title><p>Current obstacles in the treatment of KD include the lack of standard clinical and genetic markers for early diagnosis, possible severe side effect of AAS (Reye's syndrome), and the refractory KD cases with resistance to IVIG therapy, therefore, this review has focused on introducing the current advances in the identification of genetic susceptibility genes, environmental factors, diagnostic markers and adjuvant pharmacological intervention for KD.</p></sec><sec><title>Results</title><p>With an overall update in the development of KD from different aspects, our current bioinformatics data has suggested CASP3, CD40 and TLR4 as the possible pathogenic factors or diagnostic markers of KD. Besides, a list of herbal medicines which may work as the adjunct therapy for KD via targeting different proposed molecular targets of KD have also been summarized.</p></sec><sec><title>Conclusion</title><p>With the aid of modern pharmacological research and technology, it is anticipated that novel therapeutic remedies, especially active herbal chemicals targeting precise clinical markers of KD could be developed for accurate diagnosis and treatment of the disease.</p></sec></abstract><kwd-group id="keys0001"><title>Keywords</title><kwd>Kawasaki disease</kwd><kwd>Epidemiology</kwd><kwd>Diagnostic marker</kwd><kwd>Susceptibility genes</kwd><kwd>Adjuvant therapy</kwd><kwd>Herbal chemicals</kwd></kwd-group><kwd-group id="keys0002"><title>Abbreviations</title><kwd>AAS, acetylsalicylic acid</kwd><kwd>AHA, the American Heart Association</kwd><kwd>CALs, coronary artery lesions</kwd><kwd>CASP, caspase</kwd><kwd>CD, cluster of differentiation</kwd><kwd>CRP, C-reactive protein</kwd><kwd>DAVID, Database for Annotation, Visualization and Integrated Discovery</kwd><kwd>FCGR2A, Fc fragment of immunoglobulin G, low-affinity IIa</kwd><kwd>GWAS, genome-wide association method</kwd><kwd>HAdV, the human adenovirus</kwd><kwd>IL, Interleukin</kwd><kwd>ITPKC, inositol 1,4,5-triphosphate 3-kinase</kwd><kwd>C IVIG, intravenous immunoglobulin</kwd><kwd>KD, Kawasaki disease</kwd><kwd>MyD88, myeloid differentiation factor 88</kwd><kwd>NF-&#x003ba;B, nuclear factor &#x003ba;B</kwd><kwd>RS, Reye's syndrome</kwd><kwd>SNPs, single nucleotide polymorphisms</kwd><kwd>TCMs, traditional Chinese medicines</kwd><kwd>Th, T helper</kwd><kwd>TLR4, toll-like receptor 4</kwd><kwd>TNF, tumor necrosis factor</kwd></kwd-group></article-meta></front><body><sec id="sec0001"><title>Introduction</title><p id="para0029">With the 1st suspected case reported in 1967 (<xref rid="bib0039" ref-type="bibr">Kawasaki,&#x000a0;2002</xref>), KD was identified as an acute pediatric systemic vasculitis with clinical symptoms such as sustained fever, oral mucosal lesions, pleural rash, swollen cervical lymph nodes, conjunctival hyperemia, severe swelling of hand and foot with skin peeling on fingertips. One of the most serious sequelae of KD is the inflammation of the heart arteries which lead to the formation of aneurysm and coronary artery lesions (CALs) (<xref rid="bib0017" ref-type="bibr">Denby&#x000a0;et&#x000a0;al., 2017</xref>). Besides, KD was reported to affect many different organ systems including blood vessels, mucous membranes, skins and lymph nodes (<xref rid="bib0054" ref-type="bibr">Kuwabara&#x000a0;et&#x000a0;al., 2015</xref>). With 85% of cases occur in children under 5 years old, surveys have indicated that CALs caused by KD, is gradually replacing rheumatism as the most common acquired heart disease of childhood in developed countries (<xref rid="bib0018" ref-type="bibr">Dimitriades&#x000a0;et&#x000a0;al., 2014</xref>). Although the cause of KD remains unclear, effective IVIG intervention within the therapeutic window can lower the rate of CALs formation from 25% to less than 5% (<xref rid="bib0054" ref-type="bibr">Kuwabara&#x000a0;et&#x000a0;al., 2015</xref>). It is noteworthy that in recent years, a subtype of KD, the KD shock syndrome, were also reported for its severity and correlation to the coronary artery abnormalities and IVIG resistance (<xref rid="bib0023" ref-type="bibr">Gamez&#x02010;Gonzalez&#x000a0;et&#x000a0;al., 2018</xref>). Therefore, early diagnosis and treatment of KD are particularly important. Although recent advances in the understanding of KD symptoms and treatments have substantially reduced the rate of complication of the disease, considerable efforts are required to characterize the causative cause, genetic and serological markers correlated to the pathogenesis, diagnosis and intervention of KD.</p></sec><sec id="sec0002"><title>The regional and seasonal variation in the epidemiology of KD</title><p id="para0030">Although with an increasing trend of KD incidence, the risk factors responsible for the current increase in cases remain unclear (<xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>). Japan, Korea and Taiwan were regions on the list of highest incidence rate of KD (<xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>). In Japan, according to the nationwide survey conducted in 1996, the estimated incidence rate of KD was 120-150 cases per 100,000 children under 5 year old (<xref rid="bib0008" ref-type="bibr">Burns&#x000a0;et&#x000a0;al., 2000</xref>). According to the 2017 KD national epidemiological survey in Japan, with an average number of 5000&#x02013;6000 new cases each year, the total number of KD cases have reached 362,710 (male: 209,508 and female: 153,202) (<xref rid="bib0033" ref-type="bibr">Japan,&#x000a0;2017</xref>). At 2014, the incidence of KD in Korea were 194.7 per 100,000 children under 5 year old (<xref rid="bib0042" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2017a</xref>). Although national occurrence of KD was reported in past years, seasonal peaks of KD incidence were also reported in many geographic regions (<xref rid="bib0008" ref-type="bibr">Burns&#x000a0;et&#x000a0;al., 2000</xref>). For example, the peak of KD incidence occurs in January and July in Japan, while in mainland China and Taiwan, the peak of KD incidence was reached from December to January and June to July. In USA, Australia, Canada and Europe, while a higher of KD incidence rate was observed during the winter months (<xref rid="bib0024" ref-type="bibr">Ha&#x000a0;et&#x000a0;al., 2016</xref>; <xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>), no significant seasonal variation of KD was reported in Korea (<xref rid="bib0100" ref-type="bibr">Rhim&#x000a0;et&#x000a0;al., 2019</xref>; <xref rid="bib0101" ref-type="bibr">Rhim&#x000a0;et&#x000a0;al., 2014</xref>). With an overall higher incidence rate of KD in males than in females, the male-to-female ratio was about 1.33, 1.42 and 1.62 in Japan, Korea, and Taiwan, respectively (<xref rid="bib0024" ref-type="bibr">Ha&#x000a0;et&#x000a0;al., 2016</xref>; <xref rid="bib0071" ref-type="bibr">Lue&#x000a0;et&#x000a0;al., 2014</xref>; <xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>).</p></sec><sec id="sec0003"><title>Evolutionary change in the diagnostic criteria of KD</title><p id="para0031">According to the American Heart Association (AHA) diagnostic guidelines (2004) and the international symposium diagnostic guidelines (2002), 6 classic clinical symptoms and criteria for the diagnosis of KD are listed (<xref rid="bib0002" ref-type="bibr">Ayusawa&#x000a0;et&#x000a0;al., 2005</xref>; <xref rid="bib0108" ref-type="bibr">Saguil&#x000a0;et&#x000a0;al., 2015</xref>). As a general principle, continued high fever (&#x0003e; 39&#x000a0;&#x000b0;C) lasting for at least 5 days with no response to antibiotics and antipyretics, with the development of at least 4 out of 5 listed classic diagnostic symptoms including polymorphous rash, conjunctivitis, cervical lymphadenopathy, changes in oral or extremities, could be diagnosed as KD (<xref rid="bib0051" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2015b</xref>). In addition to the assessment on clinical symptoms, laboratory diagnosis of cardiovascular damages such as chest X-ray findings, electrocardiogram changes, auscultation, aneurysm of peripheral arteries other than coronary, 2D echocardiography, angina pectoris or myocardial infarction are also important supplements for the diagnosis of KD (<xref rid="bib0002" ref-type="bibr">Ayusawa&#x000a0;et&#x000a0;al., 2005</xref>; <xref rid="bib0108" ref-type="bibr">Saguil&#x000a0;et&#x000a0;al., 2015</xref>). Other supplementary diagnostic references such as platelets counts are also applied for the diagnosis of suspected cases of KD (<xref rid="bib0106" ref-type="bibr">Ruan&#x000a0;et&#x000a0;al., 2013</xref>). In fact, the diagnostic guidelines for KD have been revised for 5 times in Japan, and with its major changes listed in <xref rid="tbl0001" ref-type="table">Table&#x000a0;A</xref>
. Now, the 2005 diagnostic guidelines (5<sup>th</sup> revision) are commonly used for the diagnosis of KD in Japan. With the current diagnostic guidelines set by the AHA in 2017, the diagnostic criteria in US has been revised for 3 times since 2004, and with its major changes listed in <xref rid="tbl0002" ref-type="table">Table&#x000a0;B</xref>
. Besides, Korea, China and Europe are countries which have adopted the AHA guidelines (2017) as the reference to the diagnosis of KD. Although with standardized diagnostic criteria compiled, due to variability of clinical symptoms in different cases, discrepancies in the interpretation of clinical signs and symptoms have led to undiagnosed and unreported cases of KD (<xref rid="bib0002" ref-type="bibr">Ayusawa&#x000a0;et&#x000a0;al., 2005</xref>; <xref rid="bib0016" ref-type="bibr">Daniels&#x000a0;et&#x000a0;al., 2012</xref>). However, recent report has suggested the evaluation on the systemic inflammatory parameters such as C-reactive protein (CRP), neutrophil differential, albumin and hemoglobin in the early phase of acute KD, are critical for the early diagnosis of KD (<xref rid="bib0110" ref-type="bibr">Seo&#x000a0;et&#x000a0;al., 2018</xref>). Consistently, additional study has suggested the increased level of immunoglobulin and platelets in the recovery phase of KD, may indicate the degree of systemic inflammation in acute KD (<xref rid="bib0025" ref-type="bibr">Han&#x000a0;et&#x000a0;al., 2017</xref>).<table-wrap position="float" id="tbl0001"><label>Table A</label><caption><p>Evolution of diagnostic guide for KD in Japan from 1970 to 2005.</p></caption><alt-text id="alt0003">Table A</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="left" valign="top">Japan</th></tr><tr><th align="left" valign="top">Year</th><th valign="top">Evolution in the major changes of diagnostic criteria for KD</th><th align="left" valign="top">References</th></tr></thead><tbody><tr><td align="left" rowspan="6" valign="top">1970</td><td valign="top">1) Fever lasts for 1&#x02013;2 weeks and with no therapeutic effect after antibiotic treatment.</td><td align="left" rowspan="6" valign="top"><xref rid="bib141" ref-type="bibr">Kawasaki et al., 1974</xref></td></tr><tr><td valign="top">2) Bilateral conjunctival hyperemia.</td></tr><tr><td valign="top">3) Lip and oral changes: dry lips, redness, cleft palate, tongue nipple bulge, diffuse oral and pharyngeal mucosa.</td></tr><tr><td valign="top">4) Changes in extremities: In the early stage of the disease, redness of the palm of the hand and hard swelling of the hands and feet, membranous peeling of the metatarsal (toe) end.</td></tr><tr><td valign="top">5) Erythema of the trunk, but no blistering and scarring.</td></tr><tr><td valign="top">6) The lymph nodes are non-suppurative and grown up to &#x02265;1.5&#x000a0;cm in diameter.</td></tr><tr><td align="left" rowspan="3" valign="top">1984</td><td valign="top">1) Modified the fever period from 1~2 weeks to 5 days or above.</td><td align="left" rowspan="3" valign="top"><xref rid="bib140" ref-type="bibr">Kim, 2006</xref></td></tr><tr><td valign="top">2) Specified the number of KD symptoms that were diagnosed (at least 5 of 6 items should be confirmed).</td></tr><tr><td valign="top">3) Supplementary information such as 2D echocardiogram or coronary angiography which can confirm the diagnosis of coronary aneurysm or coronary artery dilatation (with 4 major symptoms being diagnosed).</td></tr><tr><td align="left" rowspan="3" valign="top">1988</td><td valign="top">1) The criteria of persistent fever continued for 5 days or more as a prerequisite for KD diagnosis.</td><td align="left" rowspan="3" valign="top"><xref rid="bib139" ref-type="bibr">O&#x02019;Loughlin, 1989</xref></td></tr><tr><td valign="top">2) 4 out of 5 diagnosis criteria are confirmed.</td></tr><tr><td valign="top">3) Based on the above conditions, the possibilities of other diseases need to be excluded to confirm the diagnosis.</td></tr><tr><td align="left" rowspan="5" valign="top">2002</td><td valign="top">1) Persistent fever is observed for 5 days or more in parallel with the occurrence of 5 main symptoms as the basis for the diagnosis of KD.</td><td align="left" rowspan="5" valign="top"><xref rid="bib138" ref-type="bibr">Jane et al., 2003</xref></td></tr><tr><td valign="top">2) The patient who has sustained fever for less than 5 days can also be diagnosed as KD if typical symptoms are shown.</td></tr><tr><td valign="top">3) Diagnosis according to the additional reference based on supplementary symptoms or manifestations.</td></tr><tr><td valign="top">4) Emphasize the importance of clinical diagnosis of incomplete KD, which the main symptom compliance rate does not meet the full KD diagnostic requirements.</td></tr><tr><td valign="top">5) KD can also be diagnosed if the possibilities of other diseases are ruled out, and when a patient has confirmed with the development of coronary aneurysm or coronary artery dilatation.</td></tr><tr><td align="left" rowspan="3" valign="top">2005</td><td valign="top">1) The diagnostic criteria in cases with 4 or less febrile days after early IVIG treatment are proposed to be the same as the cases with 5 or more febrile days.</td><td align="left" rowspan="3" valign="top"><xref rid="bib0002" ref-type="bibr">Ayusawa et al., 2005</xref></td></tr><tr><td valign="top">2) Emphasize the clinical importance on the diagnosis of atypical (incomplete or suspicious) cases.</td></tr><tr><td valign="top">3) The order of 6 principal symptoms of KD was rearranged as (i) Fever (ii) Conjunctival congestion (iii) Changes of lips and oral cavity (iv) Rash (v) Changes of extremities (vi) Cervical lymphadenopathy.</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl0002"><label>Table B</label><caption><p>Evolution of diagnostic guide for KD in America from 1978 to 2017.</p></caption><alt-text id="alt0004">Table B</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="left" valign="top">America</th></tr><tr><th align="left" valign="top">Year</th><th valign="top">Evolution in the major changes of diagnostic criteria for KD</th><th align="left" valign="top">References</th></tr></thead><tbody><tr><td align="left" valign="top">1978</td><td valign="top">This standard is similar to the KD diagnostic standard of Japan in 1988. The diagnostic criteria include continuous fever for &#x02265;5 days, possess 4 out of 5 major symptoms of KD, and with the possibilities of getting other diseases being ignored.</td><td align="left" valign="top"><xref rid="bib0008" ref-type="bibr">Burns&#x000a0;et&#x000a0;al.,&#x000a0;2000</xref></td></tr><tr><td align="left" valign="top">2004</td><td valign="top">In this diagnostic guide, fever lasts for longer than 5 days is an essential diagnostic criterion for KD. If there are 4 main symptoms appeared in addition to fever, typical KD can be diagnosed even the fever lasted for only 4 days. More importantly, the necessary on the diagnosis and revision of the diagnosis criteria of incomplete KD were emphasized. Also, the diagnosis procedures and evaluation of incomplete KD suspected cases were proposed.</td><td align="left" valign="top"><xref rid="bib0082" ref-type="bibr">Newburger&#x000a0;et&#x000a0;al.,&#x000a0;2004</xref></td></tr><tr><td align="left" rowspan="6" valign="top">2017</td><td valign="top">1) For the first time the coronary artery anomaly was evaluated by the Z-value, i.e. the body surface area corrected coronary lumen diameter.</td><td align="left" rowspan="6" valign="top"><xref rid="bib0108" ref-type="bibr">Saguil&#x000a0;et&#x000a0;al.,&#x000a0;2015</xref></td></tr><tr><td valign="top">2) Patients with recovery from fever lasting for &#x02265;7 days should not be excluded from KD diagnosis.</td></tr><tr><td valign="top">3) The diagnosis process on incomplete KD is simplified when compared to the 2004 version, i.e. If the child has fever &#x02265; 5 days and fulfills 2 or 3 diagnostic criteria, or has fever for &#x02265; 7 days without other confirmed reasons, can also be diagnosed as KD with the support of clinical laboratory test results.</td></tr><tr><td valign="top">4) 5 clinical observations are proposed for the consideration of diagnosis of KD (i) Baby less than 6 months with prolonged fever and irritability (ii) Long-term fever in infants with unexplained aseptic meningitis (iii) Infants or children with prolonged fever and unexplained or culture-negative shock. (iv) Infants or children with prolonged fever and cervical lymphadenitis but no response after antibiotic treatment (v) Long-term fever in infants or children after antibiotic treatment towards cellulitis in pharynx.</td></tr><tr><td valign="top">5) It is proposed that elevated N-terminal B-type brain natriuretic peptide (NT-BNP) only suggests cardiac involvement but cannot be used for KD diagnosis.</td></tr><tr><td valign="top">6) It is suggested that KD patients with shock are prone to IVIG resistant, coronary artery complications, mitral regurgitation, prolonged myocardial insufficiency and other clinical manifestations.</td></tr></tbody></table></table-wrap></p><p id="para0032">Although the therapeutic strategy for different types of KD remains the same, cases of KD are classified into stereotype, non-stereotype and incomplete type according to the clinical symptoms of patient. In Japan, in accordance with the 2005 diagnostic guidelines (5<sup>th</sup> revision), KD patients are divided into 3 different types: (1) Complete KD with at least 5 developed classic KD symptoms, including (i) fever persisting for 5 days or more (inclusive of cases in whom the fever has subsided before the 5<sup>th</sup> day in response to therapy), (ii) bilateral conjunctival congestion, (iii) changes of lips and oral cavity such as reddening of lips, strawberry tongue, diffuse injection of oral and pharyngeal mucosa, (iv) polymorphous exanthema, (v) changes of peripheral extremities progressing from reddening of palms and soles, edema to the convalescent stage of membranous desquamation from fingertips, (vi) acute non-purulent cervical lymphadenopathy; (2) Incomplete KD with sustained fever for 5 days which was accompanied by 2 or 3 classic KD symptoms, together with the diagnosis based on 2D echocardiography or coronary angiography to rule out the possibility of other diseases; (3) Atypical KD according to doctor's evaluation on patients with no more than 4 classic KD symptoms, but accompanied by acute diarrhea, upper airway obstruction, proteinuria, nephritis, shock, massive lymphadenopathy, meningitis, blindness, intermittent deafness or other clinical symptoms (<xref rid="bib0002" ref-type="bibr">Ayusawa&#x000a0;et&#x000a0;al., 2005</xref>).</p><p id="para0033">Based on the statistics of the national epidemiological survey of KD in Japan at 2017, the percentage of stereotype and non-stereotype of KD were 77.8% and 1.6%% respectively, while 20.6% of cases were referred as incomplete type (<xref rid="bib0033" ref-type="bibr">Japan,&#x000a0;2017</xref>) . It is noteworthy that there is an increasing incidence of incomplete KD case reported with mild symptom, a lower incidence of CALs, decreased count on CRP and platelet, together with an increased level of albumin and hemoglobin when compared to previous cases (<xref rid="bib0041" ref-type="bibr">Kil&#x000a0;et&#x000a0;al., 2017</xref>). All these have suggested that advances in the diagnosis of incomplete KD, such as by evaluating the presence of anterior uveitis symptoms (<xref rid="bib0060" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2016</xref>), are needed to facilitate the precise identification of KD patients for early IVIG treatment to minimize undiagnosed cases.</p></sec><sec id="sec0004"><title>Pathogenesis of KD: from ambient environment to immunology and genetic regulation</title><p id="para0034">KD is highly correlated to the increased level of circulating inflammatory and immune cells which infiltrate into the vascular endothelial cells via systemic vasculitis. Instead of contributing by a single gene, multiple genes regulating inflammatory, cardiovascular and immune responses were reported to be associated with the pathogenesis of KD (<xref rid="bib0051" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2015b</xref>)<italic>.</italic> Further studies have shown that KD may be triggered by pathogenic microbial or viral infections, leading to inflammatory and immune responses mediated by T cells, and ultimately the destruction of vascular endothelial function with inflammatory lesions (<xref rid="bib0104" ref-type="bibr">Rowley&#x000a0;et&#x000a0;al., 2008</xref>).</p><sec id="sec0005"><title>Regional dietary and environmental factors contributing to KD</title><p id="para0035">With the increasing incidence of KD in recent years, the role of environmental factors on the epidemiology of KD has been investigated. Rodo et&#x000a0;al. suggested the northeastern China may be a source for the wind-borne pathogen of KD in Japan (<xref rid="bib0102" ref-type="bibr">Rodo&#x000a0;et&#x000a0;al., 2014</xref>). Other studies suggested the incidence of KD in Shanghai of China was increased with the exposure to high temperature and was independent to the factor of air pollution (<xref rid="bib0066" ref-type="bibr">Lin&#x000a0;et&#x000a0;al., 2017</xref>; <xref rid="bib0134" ref-type="bibr">Zeft&#x000a0;et&#x000a0;al., 2016</xref>). In Taiwan, prolonged exposure to ozone was associated with a higher risk of KD (<xref rid="bib0038" ref-type="bibr">Jung&#x000a0;et&#x000a0;al., 2017</xref>). Recent studies have also depicted various dietary factors are interlinked with the pathogenesis of KD, for example, the consumption of soy was correlated to a higher risk of KD (<xref rid="bib0094" ref-type="bibr">Portman&#x000a0;et&#x000a0;al., 2016</xref>). Further pediatric research indicated that the intake of isoflavone beyond the age of conferred maternal immunity, instead of maternal- fetal transmission of isoflavones, is correlated to the higher incidence of KD in Asia than in Western countries which have relatively lower soy or isoflavone consumption (<xref rid="bib0093" ref-type="bibr">Portman,&#x000a0;2013</xref>). In Korea, report has postulated the pathogenesis of KD may be triggered by the variants in normal flora of genetically susceptible children, which are highly related to environmental factors. Therefore, all these may help to explain the epidemiological and regional characteristics of KD (<xref rid="bib0058" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2007</xref>).</p></sec><sec id="sec0006"><title>Linking up various infectious agents with the pathogenesis of KD</title><p id="para0036">With the fact that most of the clinical symptoms such as fever, rash, conjunctivitis, cervical lymphadenopathy, and the epidemiological and laboratory characteristics of KD are similar to the classical symptoms of inflammation (<xref rid="bib0002" ref-type="bibr">Ayusawa&#x000a0;et&#x000a0;al., 2005</xref>; <xref rid="bib0024" ref-type="bibr">Ha&#x000a0;et&#x000a0;al., 2016</xref>; <xref rid="bib0033" ref-type="bibr">Japan,&#x000a0;2017</xref>; <xref rid="bib0071" ref-type="bibr">Lue&#x000a0;et&#x000a0;al., 2014</xref>; <xref rid="bib0108" ref-type="bibr">Saguil&#x000a0;et&#x000a0;al., 2015</xref>; <xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>), therefore, KD is also suggested as an infectious disease. However, there is still no definite test to differentiate KD from other diseases such as scarlet fever, juvenile rheumatoid arthritis, toxic shock syndrome or measles that cause similar symptoms (<xref rid="bib0074" ref-type="bibr">Maconochie,&#x000a0;2004</xref>; <xref rid="bib0092" ref-type="bibr">Pilania&#x000a0;and Singh,&#x000a0;2020</xref>; <xref rid="bib0105" ref-type="bibr">Rowley&#x000a0;and Shulman,&#x000a0;1998</xref>). Therefore, physical examination and tests such as urine and blood tests, electrocardiogram and echocardiogram are required for the diagnosis of KD. AHA has published the supplemental laboratory criteria on the level of CRP, white blood cell, hemoglobin, platelet, serum albumin, alanine aminotransferase and urine white blood cell for the diagnosis of incomplete KD, these laboratory characteristics have implied that infection factors are closely related to KD (<xref rid="bib0108" ref-type="bibr">Saguil&#x000a0;et&#x000a0;al., 2015</xref>). However, as the infectious factors of KD remains un-elucidated, classical methods such as microbial culture, microscopy and polymerase chain reaction are still not commonly applied for the diagnosis of KD. Consistent with the seasonal cycles of infectious diseases, the epidemiological characteristics and the incidence of KD were disparate in different seasons (<xref rid="bib0024" ref-type="bibr">Ha&#x000a0;et&#x000a0;al., 2016</xref>; <xref rid="bib0033" ref-type="bibr">Japan,&#x000a0;2017</xref>; <xref rid="bib0071" ref-type="bibr">Lue&#x000a0;et&#x000a0;al., 2014</xref>; <xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>). According to the available data, there were 3 large-scale national epidemic outbreaks of KD in Japan at 1979, 1982 and 1986, respectively (<xref rid="bib0033" ref-type="bibr">Japan,&#x000a0;2017</xref>).</p><p id="para0037">Studies have reported the possible microbes or microbe-derived substances that may cause the pathogenesis of KD, such as <italic>rickettsia</italic>-like agent, <italic>chlamydia pneumoniae, mycoplasma pneumoniae, rickettsia</italic> organisms, <italic>propionibacterium acnes, leptospira</italic> spp, <italic>yersinia pseudotuberculosis</italic>, retrovirus, measles, chickenpox, human herpesvirus 6, cytomegalovirus, group A <italic>streptococcus</italic>, dengue fever virus, epstein-barr virus, coronavirus, parvovirus B19, <italic>bacillus cereus</italic>, human bocavirus, <italic>staphylococcus</italic>, staphylococcal or streptococcal superantigens (<xref rid="bib0011" ref-type="bibr">Chang&#x000a0;et&#x000a0;al., 2014</xref>; <xref rid="bib0104" ref-type="bibr">Rowley&#x000a0;et&#x000a0;al., 2008</xref>). A recent report by Rhim et&#x000a0;al. has suggested a presumed etiology of KD which may be associated with the pathogens of acute pyelonephritis and exanthem subitum (<xref rid="bib0037" ref-type="bibr">Jung-Woo&#x000a0;et&#x000a0;al., 2019</xref>). Furthermore, Jordan et&#x000a0;al. reported that up to 8.8% of KD children had acquired upper respiratory tract infection simultaneously (<xref rid="bib0036" ref-type="bibr">Jordan-Villegas&#x000a0;et&#x000a0;al., 2010</xref>). Therefore, the report has suggested the prescription of IVIG therapy to suspected KD children without classic clinical symptoms but with recorded respiratory viral infections. Some studies have suggested the human adenovirus (HAdV) as one of the pathogens triggering KD (<xref rid="bib0022" ref-type="bibr">Fukuda&#x000a0;et&#x000a0;al., 2017</xref>; <xref rid="bib0032" ref-type="bibr">Jaggi&#x000a0;et&#x000a0;al., 2013</xref>). For example, Fukuda et&#x000a0;al. reported the case of 1 monozygotic twins who have been sequentially diagnosed with KD in conjunction with HAdV-3 infection (<xref rid="bib0022" ref-type="bibr">Fukuda&#x000a0;et&#x000a0;al., 2017</xref>). Jaggi et&#x000a0;al. reported 77 cases of KD patients were diagnosed with HAdV infection by quantitative polymerase chain reaction (<xref rid="bib0032" ref-type="bibr">Jaggi&#x000a0;et&#x000a0;al., 2013</xref>). Although with the close correlation between various infectious factors and KD, unlike other childhood infectious diseases with known infectious factors or vaccines, the infectious agent contributing to the pathogenesis of KD remains un-characterized and more studies are required.</p></sec><sec id="sec0007"><title>Immunopathogenesis of KD</title><p id="para0038">Immunological abnormalities with the development of coronary artery lesions were involved in the pathogenesis of KD. It was proposed by Lee et&#x000a0;al. that the immunopathogenesis of KD is based on a &#x0201c;protein homeostasis system&#x0201d; that controls the pathogenic toxic proteins which spread and bind to endothelial cells of coronary arteries, with the involvement of non-specific T cells and non-specific antibodies to produce various cytokines contributing to endothelial cell injury (<xref rid="bib0059" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2012a</xref>). While both the innate and acquired systems are activated after pathogen infection, clinical and laboratory studies have found that the occurrence of KD is related to the activation of the innate immune system (<xref rid="bib0026" ref-type="bibr">Hara&#x000a0;et&#x000a0;al., 2016</xref>). Broderick et&#x000a0;al. reported 4 cases of KD with the reoccurrence of inflammatory clinical symptoms similar to those in &#x0201c;recurrent fever syndrome&#x0201d; existed in febrile disease due to the dysregulation of innate immune system (<xref rid="bib0005" ref-type="bibr">Broderick&#x000a0;et&#x000a0;al., 2011</xref>).</p><p id="para0039">The acquired immune system has both cell-mediated immunity and humoral immunity. The cell-mediated immunity activates macrophages, T cells (cluster of differentiation (CD) 4+ or CD8+) and releases lymphokines. Rowley et&#x000a0;al. showed that chronic coronary arteritis in KD continued long after the onset of the disease via upregulation of T lymphocyte and type I interferon genes (<xref rid="bib0103" ref-type="bibr">Rowley&#x000a0;et&#x000a0;al., 2017</xref>). Other studies reported the increased plasma level of T helper cell type (Th) 1 cytokines (interferon-&#x003b3;, interleukin (IL)-2) and Th2 cytokines (IL-4 and IL-10) during the acute stage of KD (<xref rid="bib0061" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2015b</xref>), suggesting that both Th1 and Th2 cells may be activated simultaneously during the acute stage of KD. In recent years, with the research focus on identifying the key cytokines responsible for KD, tumor necrosis factor (TNF) and IL-1 have just been reported to play temporally roles in acute cardiac inflammation and the development of coronary vasculitis, respectively, which suggested the possible immunopathogenesis of KD (<xref rid="bib0117" ref-type="bibr">Stock&#x000a0;et&#x000a0;al., 2019</xref>).</p></sec><sec id="sec0008"><title>Ethnic disparities in genetic susceptibility to KD</title><p id="para0040">Recently, more evidence has suggested KD as a genetic disease. According to the 2017 epidemiological survey in Japan, the incidence rate of KD was 2.1% and 1.2% higher in children with siblings or parents, who have been diagnosed with KD (<xref rid="bib0033" ref-type="bibr">Japan,&#x000a0;2017</xref>). Besides, the incidence of KD was higher in Asian population, especially Japanese (<xref rid="bib0113" ref-type="bibr">Singh&#x000a0;et&#x000a0;al., 2015</xref>), suggesting the pathogenesis of KD caused by the abnormal immune cascade triggered by infection, may be correlated to the susceptibility of genes. On account of more monozygotic twins have been diagnosed with KD, genetic studies on the susceptibility gene loci of KD have been performed by using the candidate genes or genome-wide association method (GWAS) (<xref rid="bib0085" ref-type="bibr">Onouchi,&#x000a0;2009</xref>).</p><sec id="sec0009"><title>Candidate genes and genome-wide association studies of KD</title><p id="para0041">Candidate genes method refers to the selection of a potential site from a known gene based on the reported pathological or physiological processes of a specific disease, examined by the correlation analysis (<xref rid="bib0073" ref-type="bibr">Lv&#x000a0;et&#x000a0;al., 2013</xref>). Previous studies of candidate genes in KD were summarized in <xref rid="tbl0003" ref-type="table">Table&#x000a0;C</xref>
(<xref rid="bib0049" ref-type="bibr">Kim&#x000a0;and Kim,&#x000a0;2016</xref>; <xref rid="bib0073" ref-type="bibr">Lv&#x000a0;et&#x000a0;al., 2013</xref>; <xref rid="bib0085" ref-type="bibr">Onouchi,&#x000a0;2009</xref>, <xref rid="bib0088" ref-type="bibr">2015</xref>). For example, inositol 1,4,5-triphosphate 3-kinase C (ITPKC) is one of the 3 isoenzymes of inositol 1,4,5-trisphosphate 3-kinase that phosphorylates inositol 1,4,5-trisphosphate, which is closely related to the pathogenesis of KD (<xref rid="bib0086" ref-type="bibr">Onouchi,&#x000a0;2010</xref>).<table-wrap position="float" id="tbl0003"><label>Table C</label><caption><p>Candidate genes associated with KD.</p></caption><alt-text id="alt0005">Table C</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Immune function related genes</th></tr></thead><tbody><tr><td valign="top">CD209, NOD1, NLRP1, ANGPT1, MSH5, VWA7, FCGR2A, TNFRSF1A, CCL3L1, MMP11, PDCD1, IL18, HLA-G, CRP, HLA-B, HLA-C, CCR3, CCR2, IL1RN, IL4, SLC11A1, LTA, HP, IL-1Ra, CXCR2, CXCR1, UGT1A1, CX3CR1, PAFAH, MCP1, MMP2, HMOX1</td></tr><tr><td valign="top">Cardiovascular function related genes</td></tr><tr><td valign="top">CD40, CD40L, ETN, ITPKC, TGFBR2, ABO, PELI1, SMAD3, TGFB2, CASP3, VEGFA, MICB, MICA, IL10, IL4, IL6, IL-18, CCL5, CTLA4, MMP2, MMP3, MMP9, MMP12, FGB, CCR5, PRRC2A, ABHD16A, ITPR3, COL11A2, MBL2, MIF, TPH2, BTNL2, HLA-E, TIMP4, TNF, MMP13, TIMP2, ACE, KDR, CD40LG, AGTR1, CD14, MTHFR, FCGR2B, FCGR3A, FCGR3B, IL-1&#x003b2;, VEGFR2, LTA, TNF-&#x003b1;, eNOS, iNOS, MBL</td></tr></tbody></table><table-wrap-foot><fn><p>CD209, cluster of differentiation 209; NOD1, nucleotide-binding oligomerization domain-containing protein 1; NLRP1, NACHT, LRR, FIIND, CARD domain and PYD domains-containing protein 1; ANGPT1, angiopoietin 1; MSH5, MutS protein homolog 5; VWA7, von willebrand factor a domain containing 7; TNFRSF1A, tumor necrosis factor receptor 1; CCL3L1, chemokine (C-C motif) ligand 3-like 1; MMP11, matrix metalloproteinase-11; PDCD1, programmed cell death protein 1; IL18, interleukin-18; HLA-G, human leukocyte antigen G; HLA-B, human leukocyte antigen B; HLA-C, human leukocyte antigen C; CCR3, C-C chemokine receptor type 3; CCR2, C-C chemokine receptor type 2; IL1RN, Interleukin 1 receptor antagonist; IL4, Interleukin 4; SLC11A1, natural resistance-associated macrophage protein 1; LTA, lymphotoxin alpha; HP, haptoglobin; IL-1RA, interleukin-1 receptor antagonist; UGT1A1, UDP-glucuronosyltransferase 1-1; CX3CR1, CX3C chemokine receptor 1; MMP2, matrix metalloproteinase-2; HMOX1, heme oxygenase (decycling) 1; CD40L, cluster of differentiation 40 ligand; TGFBR2, transforming growth factor, beta receptor II; PELI1, protein pellino homolog 1; SMAD3, mothers against decapentaplegic homolog 3; TGFB2, transforming growth factor-beta 2; CASP3, caspase 3; VEGFA,v ascular endothelial growth factor A; MICB, MHC class I polypeptide-related sequence B; MICA, MHC class I polypeptide-related sequence A; IL10, Interleukin 10; IL4, Interleukin 4; IL6, Interleukin 6; IL-18, Interleukin 18; CCL5, chemokine (C-C motif) ligand 5; CTLA4, cytotoxic T-lymphocyte-associated protein 4; MMP3, matrix metalloproteinase-3; MMP9, matrix metalloproteinase-9; MMP12, matrix metalloproteinase-12; FGB, fibrinogen beta chain; CCR5, C-C chemokine receptor type 5; PRRC2A, proline-rich coiled coil 2A; ITPR3, inositol 1,4,5-trisphosphate receptor, type 3; COL11A2, collagen, type XI, alpha 2; MBL2, mannose-binding lectin 2; MIF, macrophage migration inhibitory factor; TPH2, tryptophan hydroxylase 2; BTNL2, butyrophilin-like protein 2; HLA-E, histocompatibility antigen, alpha chain E; TIMP4, metalloproteinase inhibitor 4; TIMP2, metalloproteinase inhibitor 2; TNF, tumor necrosis factor; TNF-&#x003b1;, tumor necrosis factor-&#x003b1;; MMP13, matrix metalloproteinase-13; ACE, angiotensin-converting enzyme; KDR, kinase insert domain receptor; AGTR1, angiotensin II receptor type 1; CD14, cluster of differentiation 14; MTHFR, methylene tetrahydrofolate reductase; FCGR2B, Fc region receptor II-b; FCGR3A, Fc region receptor III-A; FCGR3B, Fc region receptor III-B; IL, interleukin; VEGFR2, vascular endothelial growth factor receptor 2; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; MBL, mannan-binding lectin.</p></fn></table-wrap-foot></table-wrap></p><p id="para0042">Genome-wide association studies (GWAS), also known as whole genome association study, refers to the genome-wide high-density genetic labeling or typing of DNA samples from both health control and disease case group for the whole genome-wide comparison of small genomic variations such as the single nucleotide polymorphisms (SNPs) to identify genes that may contribute to the development to a certain disease (<xref rid="bib0051" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2015b</xref>; <xref rid="bib0073" ref-type="bibr">Lv&#x000a0;et&#x000a0;al., 2013</xref>). This approach has been used to identify SNPs in Parkinson's disease (<xref rid="bib0127" ref-type="bibr">Witoelar&#x000a0;et&#x000a0;al., 2017</xref>), Crohn disease (<xref rid="bib0020" ref-type="bibr">Foo&#x000a0;et&#x000a0;al., 2017</xref>), diabetes (<xref rid="bib0009" ref-type="bibr">Bush&#x000a0;and Moore,&#x000a0;2012</xref>), and heart abnormalities (<xref rid="bib0009" ref-type="bibr">Bush&#x000a0;and Moore,&#x000a0;2012</xref>)<italic>.</italic> Consistently, a SNP within ITPKC gene was highly associated with the development of coronary artery abnormalities and KD (<xref rid="bib0085" ref-type="bibr">Onouchi,&#x000a0;2009</xref>). However, findings suggested that SNPs of ITPKC susceptibility in KD may vary for different ethnicities, for example, in Japan, SNP (rs28493229) in ITPKC was associated with risk of coronary artery abnormalities, while the same ITPKC SNP in Chinese was associated with susceptibility of KD (<xref rid="bib0133" ref-type="bibr">Yang&#x000a0;et&#x000a0;al., 2012</xref>). In the European population, several genes such as calcium/calmodulin-dependent protein kinase type II delta chain, cub and sushi multiple domains 1, diacylglycerol kinase beta, E3 ubiquitin-protein ligase, N-acetylated alpha-linked acidic dipeptidase-like 2, protein phosphatase 1 regulatory subunit 14C, T-complex protein 1 subunit alpha, zinc finger homeobox 3, melanoma inhibitory activity/ras-related GTP-binding protein 4b, ITPKC (<xref rid="bib0006" ref-type="bibr">Burgner&#x000a0;et&#x000a0;al., 2009</xref>; <xref rid="bib0040" ref-type="bibr">Khor&#x000a0;et&#x000a0;al., 2011</xref>), Fc fragment of immunoglobulin G, low-affinity II a (FCGR2A), have been identified as susceptibility genes for KD through GWAS (<xref rid="bib0040" ref-type="bibr">Khor&#x000a0;et&#x000a0;al., 2011</xref>).</p><p id="para0043">Further researches have also suggested the susceptibility genes for KD are correlated to ethnicity. For example, SNPs in B lymphocyte kinase, nicotinamide mononucleotide adenylyltransferase 2, HLA class I histocompatibility antigen protein P5 and nod-like receptor family pyrin domain containing 14 were identified as susceptibility loci for pathogenesis of KD in Korean population (<xref rid="bib0048" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2017b</xref>). Besides, SNP located at the CRP locus (rs12068753) was found highly correlated to the CRP levels of KD patients in Korea (<xref rid="bib0044" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2015</xref>). Susceptible gene locus associated with KD such as protein pellino homolog 1 (<xref rid="bib0046" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2012b</xref>), 1p31 (<xref rid="bib0045" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2011</xref>), coatomer subunit beta, endoplasmic reticulum aminopeptidase 1, immunoglobulin heavy-chain variable, BLK, human leukocyte antigen (HLA) (<xref rid="bib0084" ref-type="bibr">Oh&#x000a0;et&#x000a0;al., 2008</xref>), CD40 and FCGR2A (<xref rid="bib0055" ref-type="bibr">Kwon&#x000a0;et&#x000a0;al., 2017</xref>) (<xref rid="tbl0004" ref-type="table">Table&#x000a0;D</xref>
) were identified in the Asian population (<xref rid="bib0087" ref-type="bibr">Onouchi,&#x000a0;2012</xref>). In addition, genetic variants in FCGR2A or CD40 have also been depicted in KD patients of different nationalities including Chinese (<xref rid="bib0034" ref-type="bibr">Ji&#x000a0;et&#x000a0;al., 2013</xref>), European (<xref rid="bib0063" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2012b</xref>), Korean, Australian and New Zealander (<xref rid="bib0040" ref-type="bibr">Khor&#x000a0;et&#x000a0;al., 2011</xref>). Of note, SNPs (rs4810485 and rs1535045) within CD40 gene were associated with the development of KD in Taiwanese children (<xref rid="bib0052" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2012</xref>). Although literature has reported the possible genetic role of FCGR2A alleles for the pathophysiology of KD in Chinese children (<xref rid="bib0131" ref-type="bibr">Yan&#x000a0;et&#x000a0;al., 2013</xref>), other studies reported that there is no correlation between the SNP (rs1801274) of FCGR2A gene and the incident of KD in patients of Greeks origin (<xref rid="bib0013" ref-type="bibr">Chatzikyriakidou&#x000a0;et&#x000a0;al., 2015</xref>; <xref rid="bib0095" ref-type="bibr">Qian&#x000a0;et&#x000a0;al., 2013</xref>). In Japan, while the number of CC chemokine ligand 3-like 1 gene copies is highly associated with the occurrence of KD and IVIG resistance, there were no correlation to the pathogenesis of KD in Korean patients (<xref rid="bib0043" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2012a</xref>), suggesting the susceptibility genes for KD may be specific to ethnicity according to the results of GWAS.<table-wrap position="float" id="tbl0004"><label>Table D</label><caption><p>KD-related genes reported by genome-wide association studies.</p></caption><alt-text id="alt0006">Table D</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Genome-wide association studies</th></tr></thead><tbody><tr><td valign="top">FCGR2A, BLK, CD40, HLA-DQB2, HLA-DOB, NFKBIL1, MPO, LTA, NAALADL2, ZFHX3, DAB1, PELI1, COPB2, ERAP1, IGHV, CAMK2D, CSMD1, DGKB, LNX1, PPP1R14C, TCP1, MIA/RAB4B</td></tr></tbody></table><table-wrap-foot><fn><p>HLA-DQB2, HLA class II histocompatibility antigen, DX beta chain; HLA-DOB, NFKBIL1, NF-kappa-B inhibitor-like protein 1; ZFHX3, Zinc finger homeobox protein 3; DAB1, disabled-1; ERAP1, Endoplasmic reticulum aminopeptidase 1; IGHV, immunoglobulin heavy chain; CAMK2D, Calcium/calmodulin-dependent protein kinase 2D; CSMD1, calcium-binding and sushi multiple domains 1; DGKB, diacylglycerol kinase beta; LNX1, ligand of numb-protein X 1; PPP1R14C, protein phosphatase 1 regulatory subunit 14C; TCP1,T -complex protein 1 subunit alpha; MPO, myeloperoxidase.</p></fn></table-wrap-foot></table-wrap></p><p id="para0044">Although the discrepancy between ethnicity was not well-defined, with the importance of CALs and IVIG resistance in the pathogenesis of KD, potassium intermediate/small conductance calcium-activated channel was identified as a susceptibility locus for the development of CALs in KD (<xref rid="bib0047" ref-type="bibr">Kim&#x000a0;et&#x000a0;al., 2013</xref>). In addition, SNP (rs1801274) on FCGR2A is also one of the factors influencing the curative effect of IVIG on KD (<xref rid="bib0034" ref-type="bibr">Ji&#x000a0;et&#x000a0;al., 2013</xref>). <xref rid="bib0051" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al.&#x000a0;(2015a,b)</xref> reported that hypomethylation of FCGR2A is correlated to KD and resistance to IVIG (<xref rid="bib0050" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2015a</xref>), suggesting the possible role of susceptibility genes in the development of CAL or IVIG resistance.</p></sec><sec id="sec0010"><title>Bioinformatics analysis on genes responsible for the pathophysiology of KD</title><p id="para0045">To summarize and integrate the genes responsible for the pathogenesis of KD, we have further analyzed the KD-related genes reported by literatures from 1970 to 2018. Among them, 25 KD related pathways and 229 KD related genes were sorted out and interpreted by the functional annotation tool in the bioinformatics resource &#x0201c;Database for Annotation, Visualization and Integrated Discovery&#x0201d; (DAVID), STRING and Uniprot, for the discovery of the enriched functional-related gene groups (<xref rid="bib0029" ref-type="bibr">Huang&#x000a0;et&#x000a0;al., 2009</xref>). The data collected from DAVID functional annotation clustering were then input to software cytoscape enrichment plugin, with a genetic network summarized in <xref rid="fig0001" ref-type="fig">Fig. A</xref>
. According to the enrichment score of DAVID, 3 genes including toll-like receptor 4 (TLR4), caspase (CASP)-3 and CD40 are identified as the most enriched genes for KD. Firstly, TLR4 is one of toll-like receptors which level was found upregulated on peripheral blood mononuclear/macrophage cells in acute KD patients when compared to healthy children of the same age (<xref rid="bib0120" ref-type="bibr">Wang&#x000a0;et&#x000a0;al., 2008</xref>). Together with the elevated expression of related molecules myeloid differentiation protein-2 and myeloid differentiation factor 88 (MyD88), it was suggested that abnormal activation of TLR4 may be one of the initiating factors leading to immune dysfunction in KD patients, which also involved the activation of the nuclear factor &#x003ba;B (NF-&#x003ba;B) and its downstream pathway with the excessive production of pro-inflammatory cytokines such as TNF-&#x003b1; (<xref rid="bib0120" ref-type="bibr">Wang&#x000a0;et&#x000a0;al., 2008</xref>).<fig id="fig0001"><label>Fig. A</label><caption><p>The bioinformatic analysis on KD-enriched genes. By summarizing previous literatures reported on genes involved in pathogenesis of KD, this graph was generated by Cytoscape software with the data collected from the DAVID annotation tools, which predicted the most enriched KD pathways. Among them, TLR4, CASP3 and CD40 are the most important genes that are predicted to be involved in the KD pathways and may represent as a potential gene marker for the diagnosis or treatment of KD. The genes with more linkages are of higher importance to the modulation of KD.</p></caption><alt-text id="alt0001">Fig. A</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="para0046">Consistent with our bioinformatics data, CASP3 is reported to be associated with the formation of coronary lesions in KD patients (<xref rid="bib0090" ref-type="bibr">Onouchi&#x000a0;et&#x000a0;al., 2011</xref>). Besides, other than its basic role in triggering apoptosis, the interaction of CASP3 with the T cell receptor, was correlated to the increased transcription of CASP3 and activation of the nuclear factor of activated T-cells signaling pathway, accompanied by the increased level of cytokines such as IL-2 (<xref rid="bib0089" ref-type="bibr">Onouchi&#x000a0;et&#x000a0;al., 2010</xref>; <xref rid="bib0128" ref-type="bibr">Wu&#x000a0;et&#x000a0;al., 2006</xref>). With the fact that there are different protein substrates for CASP3, therefore, further investigation on the immuno-regulatory role of CASP3 in the pathogenesis of KD is highly desired. Literature has also showed that the expression level of CD40 was significantly higher in both acute KD and KD with coronary artery lesion groups, suggesting the possible immunological role of CD40 in the pathogenesis of KD, which may be modulated through the MyD88-independent-Toll-like receptor 4 transduction pathway (<xref rid="bib0121" ref-type="bibr">Wang&#x000a0;et&#x000a0;al., 2007</xref>). Collectively, together with the literatures supporting the pathogenic roles of different genes in KD, the current bioinformatics data may provide useful information for the searching of potential drug targets, gene markers or regulatory pathways of KD, which provide practitioners or researchers in the field with clue for further investigation.</p></sec></sec></sec><sec id="sec0011"><title>Limitations and side effects of the combined therapy of IVIG and AAS</title><p id="para0047">Until now, while the etiology of KD remains un-elucidated, the therapy for all types of KD is still limited on the combinational use of IVIG and AAS at different stages of KD. In IVIG resistance or refractory KD, clinicians may need to apply a second dose of IVIG, with additional treatment designated for anti-vascular inflammation (<xref rid="bib0082" ref-type="bibr">Newburger&#x000a0;et&#x000a0;al., 2004</xref>). Reports have depicted around 25&#x02013;30% of untreated KD patients developed CALs including coronary artery dilation, aneurysms or fistula formation (<xref rid="bib0051" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2015b</xref>). However, approximately 10% of KD patients did not respond to IVIG treatment, and eventually led to a higher risk of CALs formation or KD shock syndrome (<xref rid="bib0007" ref-type="bibr">Burns&#x000a0;and Glode,&#x000a0;2004</xref>; <xref rid="bib0023" ref-type="bibr">Gamez&#x02010;Gonzalez&#x000a0;et&#x000a0;al., 2018</xref>; <xref rid="bib0051" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2015b</xref>).</p><p id="para0048">Combined therapy of IVIG and AAS administered for reducing the incidence of coronary artery abnormalities, anti-inflammatory and anti-platelet in the acute phase of KD, has been adopted as a standard KD therapy for many years (<xref rid="bib0111" ref-type="bibr">Shulman&#x000a0;and Rowley,&#x000a0;2015</xref>). The prevalence of coronary abnormalities was inversely related to the total dose of IVIG and independent of the dose of AAS (30&#x02013;50&#x000a0;mg/kg per day in Japan and 80&#x02013;100&#x000a0;mg/kg per day in North America) during the acute phase (<xref rid="bib0119" ref-type="bibr">Terai&#x000a0;and Shulman,&#x000a0;1997</xref>).</p></sec><sec id="sec0012"><title>The prognosis of IVIG resistance</title><p id="para0049">IVIG resistance was defined as the persistent fever for 48&#x000a0;h after completion of IVIG treatment (<xref rid="bib0112" ref-type="bibr">Singer&#x000a0;et&#x000a0;al., 2008</xref>) . About 10&#x02013;20% of KD patients were reported as not responsive to the treatment of IVIG and high-dose AAS, and with a higher risk of developing coronary heart disease complications (<xref rid="bib0112" ref-type="bibr">Singer&#x000a0;et&#x000a0;al., 2008</xref>). Some reports have suggested several biomarkers and genetic polymorphisms can be applied to predict resistance to IVIG such as clusterin (<xref rid="bib0091" ref-type="bibr">Ou-Yang&#x000a0;et&#x000a0;al., 2013</xref>), IL-6 (<xref rid="bib0109" ref-type="bibr">Sato et&#x000a0;al., 2013</xref>), IL-10 (<xref rid="bib0125" ref-type="bibr">Wang&#x000a0;et&#x000a0;al., 2013</xref>), IL-17 (<xref rid="bib0035" ref-type="bibr">Jia&#x000a0;et&#x000a0;al., 2010</xref>), TNF-&#x003b1; (<xref rid="bib0125" ref-type="bibr">Wang&#x000a0;et&#x000a0;al., 2013</xref>), and CD4<sup>+</sup> CD25<sup>+</sup> forkhead box P3 regulatory T cells (<xref rid="bib0035" ref-type="bibr">Jia&#x000a0;et&#x000a0;al., 2010</xref>). Some laboratory indicators are also important for the prediction of IVIG responsiveness, for example, age, sex, number of illness days, platelet count, erythrocyte sedimentation rate, aspartate aminotransferase, hemoglobin concentration, CRP, eosinophil, total bilirubin, lactate dehydrogenase (<xref rid="bib0053" ref-type="bibr">Kuo&#x000a0;et&#x000a0;al., 2007</xref>; <xref rid="bib0114" ref-type="bibr">Sleeper&#x000a0;et&#x000a0;al., 2011</xref>), cholesterol (<xref rid="bib0031" ref-type="bibr">Hwang&#x000a0;et&#x000a0;al., 2011</xref>), serum albumin (<xref rid="bib0057" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2015a</xref>), percentage of neutrophils, and serum sodium level (<xref rid="bib0079" ref-type="bibr">Moon&#x000a0;et&#x000a0;al., 2016</xref>). Although there are still no definite treatments for KD patients with IVIG resistance, steroid such as prednisolone was reported to reduce the incidence of coronary abnormalities (<xref rid="bib0078" ref-type="bibr">Miyata&#x000a0;et&#x000a0;al., 2018</xref>). Infliximab (<xref rid="bib0115" ref-type="bibr">Son&#x000a0;et&#x000a0;al., 2011</xref>), methotrexate (<xref rid="bib0062" ref-type="bibr">Lee&#x000a0;et&#x000a0;al., 2008</xref>) and plasma exchange (<xref rid="bib0028" ref-type="bibr">Hokosaki&#x000a0;et&#x000a0;al., 2012</xref>) have also been reported to benefit KD patients with initial IVIG treatment failure. Among them, infliximab was reported to process good adjuvant efficacy for KD patients with IVIG resistance by reducing duration of fever, improving IVIG reaction rate and level of specific inflammatory marker. This observation is consistent with the results of several independent clinical trials in different countries. For example, in Japan, the use of infliximab was correlated with the level of several transcripts associated with IVIG resistance factors and inflammation signaling pathways of KD such as peptidase inhibitor-3, matrix metalloproteinase-8, chemokine receptor-2 and pentamer-3 (<xref rid="bib0083" ref-type="bibr">Ogihara&#x000a0;et&#x000a0;al., 2014</xref>). In Korea, retrospective analysis of 16 patients with refractory KD indicated that infliximab can also be used to prevent the progression of CAL in the refractory KD (<xref rid="bib0116" ref-type="bibr">Song&#x000a0;et&#x000a0;al., 2010</xref>).</p><sec id="sec0013"><title>Reye's syndrome</title><p id="para0050">The possible adverse effect resulting from the standard AAS treatment after IVIG therapy is the risk of developing Reye's syndrome (RS) in KD patients (<xref rid="bib0004" ref-type="bibr">Belay&#x000a0;et&#x000a0;al., 1999</xref>; <xref rid="bib0098" ref-type="bibr">Remington&#x000a0;et&#x000a0;al., 1985</xref>). RS occurs during the treatment of fever with drugs containing AAS, and is usually preceded by a viral infection, especially influenza and chickenpox, in children and teenagers, leading to possible lethal side effects such as toxic encephalopathy or liver dysfunction (<xref rid="bib0015" ref-type="bibr">Chornomydz&#x000a0;et&#x000a0;al., 2017</xref>). The surveillance of RS was first started in the U.S. at early 1970s and has led to the restricted use of AAS in children nowadays (<xref rid="bib0012" ref-type="bibr">Chapman&#x000a0;and Arnold,&#x000a0;2020</xref>). Besides, according to the AHA diagnostic guidelines of KD (2017), KD patients who have been prescribed with high dose of AAS treatment are at the possible risk of getting RS, and therefore replacing the AAS with another antiplatelet drug is recommended (<xref rid="bib0076" ref-type="bibr">McCrindle&#x000a0;et&#x000a0;al., 2017</xref>). In Japan (<xref rid="bib0080" ref-type="bibr">Nejihashi&#x000a0;et&#x000a0;al., 1980</xref>), Taiwan (<xref rid="bib0126" ref-type="bibr">Wei&#x000a0;et&#x000a0;al., 2005</xref>), Hong Kong (<xref rid="bib0118" ref-type="bibr">Su et al., 2018</xref>) and the United States (<xref rid="bib0004" ref-type="bibr">Belay&#x000a0;et&#x000a0;al., 1999</xref>), although only occasional RS cases were reported, finding an alternative anti-inflammatory drug or herbal compounds that replaces AAS is desirable.</p></sec></sec><sec id="sec0014"><title>Herbal chemicals as the effective adjuvant therapy to KD</title><p id="para0051">In fact, many studies have proposed the use of traditional Chinese medicines (TCMs) or natural products as a supplementary therapy for the KD (<xref rid="tbl0005" ref-type="table">Table&#x000a0;E</xref>
). For example, resveratrol from <italic>Vitis vinifera L.</italic> (fruit) possesses anti-inflammatory effects on human coronary arterial endothelial cells via decreasing the level of TNF-&#x003b1;-induced expression of intercellular adhesion molecule-1, inducible nitric oxide synthase and IL-1&#x003b2; and autophagy (<xref rid="bib0030" ref-type="bibr">Huang&#x000a0;et&#x000a0;al., 2017</xref>). Besides, low dose of resveratrol could protect against experimental induced RS partially via inhibition of oxidative stress and restoration of complex I activity (<xref rid="bib0001" ref-type="bibr">Abdin&#x000a0;and Sarhan,&#x000a0;2014</xref>). Based on the above observation, natural product may work as a possible supplement for applying with AAS in infants and young children to reduce the risk of RS or other side effect. On the other hand, triptolide from <italic>Tripterygium wilfordii Hook.f</italic> (root) could reduce the expression of intercellular adhesion molecule-1 in endothelial cells and increase the rate of apoptosis of inflammatory cells in a mouse model of KD (<xref rid="bib0132" ref-type="bibr">Yan&#x000a0;and Zou,&#x000a0;2013</xref>), suggesting triptolide may be an alternative or adjuvant anti-inflammatory agent for treating KD. According to the results of 2 independent clinical studies conducted in mainland China, the treatment of ligustrazine (an alkaloid extracted from rhizome of <italic>Ligusticum striatum DC</italic>) in combination with standard KD therapy using AAS, IVIG and anti-blood clot medicine dipyridamole, showed a significantly better improvement in relieving symptoms of increased body temperatures and coronary artery dilation, when compared to the treatment group of Western medicine alone (<xref rid="bib0072" ref-type="bibr">Luo,&#x000a0;2010</xref>; <xref rid="bib0081" ref-type="bibr">Neng&#x000a0;et&#x000a0;al., 1996</xref>). Tanshinone II-A, a natural compound extracted from <italic>Salvia miltiorrhiza Bunge</italic> (root), was also applied in combination with AAS and IVIG to treat KD. This clinical study confirmed that co-treatment of tanshinone II-A with IVIG and AAS can shorten the time of fever, reduced the level of CRP and facilitated the faster recovery of coronary artery damage when compared to standard IVIG and AAS treatment alone (<xref rid="bib0135" ref-type="bibr">Zhang&#x000a0;et&#x000a0;al., 2011</xref>).<table-wrap position="float" id="tbl0005"><label>Table E</label><caption><p>List of traditional Chinese medicines or herbal compounds used as adjuvant thearpy for treating KD with reported clinical efficacy.</p></caption><alt-text id="alt0007">Table E</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Single herbal compounds</th><th valign="top">Source</th><th valign="top">Pharmacological actions, mechanisms or signaling pathways</th><th valign="top">References</th></tr></thead><tbody><tr><td align="left" rowspan="2" valign="top">Resveratrol</td><td align="left" rowspan="2" valign="top"><italic>Vitis vinifera L.</italic>(fruit)</td><td valign="top">Decreased the level of TNF-&#x003b1;-induced expression and inducible nitric oxide synthase and IL-1&#x003b2; via the activation of autophagy</td><td valign="top"><xref rid="bib0030" ref-type="bibr">Huang&#x000a0;et&#x000a0;al.,&#x000a0;2017</xref></td></tr><tr><td valign="top">Inhibition of oxidative stress and restoration of complex I activity</td><td valign="top"><xref rid="bib0001" ref-type="bibr">Abdin&#x000a0;and Sarhan,&#x000a0;2014</xref></td></tr><tr><td valign="top">Triptolide</td><td valign="top"><italic>Tripterygium wilfordii Hook.f.</italic>(root)</td><td valign="top">Lowered the expression level of intercellular cell adhesion molecule-1 and increased the rate of apoptosis of inflammatory cells</td><td valign="top"><xref rid="bib0132" ref-type="bibr">Yan&#x000a0;and Zou,&#x000a0;2013</xref></td></tr><tr><td valign="top">Tanshinone II-A</td><td valign="top"><italic>Salvia miltiorrhiza Bunge</italic> (root)</td><td valign="top">Anti-inflammatory effect</td><td valign="top"><xref rid="bib0135" ref-type="bibr">Zhang&#x000a0;et&#x000a0;al.,&#x000a0;2011</xref></td></tr><tr><td valign="top">Ligustrazine</td><td valign="top"><italic>Ligusticum striatum DC</italic> (rhizome)</td><td valign="top">Anti-inflammatory effect</td><td valign="top"><xref rid="bib0072" ref-type="bibr">Luo,&#x000a0;2010</xref> and <xref rid="bib0081" ref-type="bibr">Neng&#x000a0;et&#x000a0;al.,&#x000a0;1996</xref></td></tr><tr><td valign="top">Herbal decoctions</td><td valign="top">Herbal composition</td><td valign="top">Pharmacological actions, mechanisms or signaling pathways</td><td valign="top">References</td></tr><tr><td valign="top">Qing Re Liang Xue decoction</td><td valign="top"><italic>Salvia miltiorrhiza Bunge, Lonicera japonica Thunb</italic> (flower)<italic>, Forsythia suspense (Thunberg) Vahl</italic> (fruit)<italic>, Anemarrhena asphodeloides Bunge</italic> (rhizome)<italic>, etc.</italic></td><td valign="top">Reduced platelet count and level of serum IL-33 and TNF-&#x003b1;, with improvement in hypercoagulable state</td><td valign="top"><xref rid="bib0014" ref-type="bibr">Chen&#x000a0;et&#x000a0;al.,&#x000a0;2015</xref></td></tr><tr><td valign="top">Yinqiao-San, Qing Ying Tang, Radix Ophiopogon soup etc.</td><td valign="top"><italic>Mentha, Forsythia suspensa (Thunberg) Vahl, Lonicera japonica Thunb, Anemarrhena asphodeloides Bunge, Cicadae Periostracum</italic> (shell of <italic>Cryptotympana pustulata Fabricius</italic>)<italic>, Uncaria rhynchophylla(Miq.) Miq. ex Havil.</italic> (hooks and stems)</td><td valign="top">Anti-inflammatory and protective effect on coronary artery</td><td valign="top"><xref rid="bib0096" ref-type="bibr">Qin&#x000a0;et&#x000a0;al.,&#x000a0;2017</xref></td></tr><tr><td valign="top">Bai Hu decoction</td><td valign="top"><italic>Gypsum fibrosum, Anemarrhena asphodeloides Bunge, O. s. ssp. japonica, Glycyrrhiza glabra L.</italic> (root)</td><td valign="top">Exerted antipyretic, anti-inflammatory effect and reduced coronary artery inflammation</td><td valign="top"><xref rid="bib0124" ref-type="bibr">Wang,&#x000a0;2011</xref></td></tr><tr><td valign="top">Jie Du Hua Yu decoction</td><td valign="top"><italic>Forsythia suspensa (Thunberg) Vahl, Lonicera japonica Thunb, Angelica sinensis (Oliv.) Diels</italic> (root)<italic>, Cicadae Periostracum, Lumbricina</italic></td><td valign="top">Anti-inflammatory and reduced coronary artery disease risk</td><td valign="top"><xref rid="bib0069" ref-type="bibr">Liu,&#x000a0;2017</xref></td></tr><tr><td valign="top">Yinqiao-San, Qingwen Baidu Yin and, Bamboo leaves gypsum soup</td><td valign="top"><italic>Forsythia suspensa (Thunberg) Vahl, Lonicera japonica Thunb, Anemarrhena asphodeloides Bunge, Cicadae Periostracum, Gypsum fibrosum, etc.</italic></td><td valign="top">Anti-inflammatory and regulated the immune system</td><td valign="top"><xref rid="bib0122" ref-type="bibr">Wang&#x000a0;and Feng,&#x000a0;2002</xref></td></tr></tbody></table></table-wrap></p><p id="para0052">In addition to single herbal chemicals, reports have also suggested the use of traditional herbal decoctions or formulations for the treatment of KD. For example, &#x0201c;Qing Re Liang Xue&#x0201d; decoction composed of <italic>Salvia miltiorrhiza Bunge, Lonicera japonica Thunb</italic> (flower)<italic>, Forsythia suspense (Thunberg) Vahl</italic> (fruit)<italic>, Anemarrhena asphodeloides Bunge</italic> (rhizome)<italic>,</italic> was prescribed with IVIG, AAS, and dipyridamole to reduce platelet count and decrease the serum level of IL-33 and TNF-&#x003b1; to improve the hypercoagulable state of KD patients (<xref rid="bib0014" ref-type="bibr">Chen&#x000a0;et&#x000a0;al., 2015</xref>), suggesting the effective use of TCMs to alleviate inflammation in KD patients. Similarly, TCMs such as <italic>Salvia miltiorrhiza Bunge, Lonicera japonica Thunb, Forsythia suspense (Thunberg) Vahl, Cortex Moutan Radicis</italic> (the root bark of <italic>Paeonia suffruticosa Andr.</italic>) can help to resume the normal blood platelet level, suppress the activation of platelet, and reduce the incidence of CAL in KD patients (<xref rid="bib0107" ref-type="bibr">Ruo-Sha&#x000a0;and Shu-Juan,&#x000a0;2008</xref>). In a cohort study of 109 cases of KD, results have indicated the combined treatment of TCMs containing &#x0201c;Yinqiao-San&#x0201d;, &#x0201c;Qing Ying Tang&#x0201d; or &#x0201c;Radix Ophiopogon soup&#x0201d;, IVIG and AAS, could help to resume the normal level of several physiological markers in KD patients (<xref rid="bib0096" ref-type="bibr">Qin&#x000a0;et&#x000a0;al., 2017</xref>). In addition, &#x0201c;Bai Hu decoction&#x0201d; can exert anti-pyretic, anti-inflammatory effect and reduce coronary artery inflammation in 32 patients with KD (<xref rid="bib0124" ref-type="bibr">Wang,&#x000a0;2011</xref>). Other reports indicated that 60 cases of KD treated by &#x0201c;Jie Du Hua Yu decoction&#x0201d; in combination with IVIG, showed a shorter symptom duration when compared with other group treated by combination of anti-infective agent (cephalosporin or penicillin) and AAS without IVIG. The clinical parameters such as CRP, erythrocyte sedimentation rate, and recovery rate of coronary artery diameter expansion in TCMs treatment group with IVIG, were improved better than the anti-infective agent and AAS combined treatment group without IVIG (<xref rid="bib0069" ref-type="bibr">Liu,&#x000a0;2017</xref>).</p><p id="para0053">Further clinical studies on the use of herbal decoction in addition to standard AAS and IVIG treatment have confirmed the effectiveness of TCMs as adjuvant therapy to KD. For example, the co-treatment of a herbal decoction containing <italic>Gypsum fibrosum, Salvia miltiorrhiza Bunge, Lonicera japonica Thunb and Forsythia suspense (Thunberg) Vahl</italic>, with AAS and IVIG, can attenuate the symptoms and the level of white blood cell, platelet, CRP and ESR, in a shorter duration than the control group with AAS and IVIG treatment only (<xref rid="bib0003" ref-type="bibr">Baoshen,&#x000a0;2018</xref>; <xref rid="bib0067" ref-type="bibr">Linlin&#x000a0;et&#x000a0;al., 2016a</xref>; <xref rid="bib0068" ref-type="bibr">Linlin&#x000a0;et&#x000a0;al., 2016b</xref>). On the other hand, TCMs have also played an important immunomodulatory role in acute phase of KD. For example, &#x0201c;Yinqiao-San&#x0201d;, &#x0201c;Qingwen Baidu Yin&#x0201d; and &#x0201c;Bamboo leaves gypsum soup&#x0201d;, could reduce the inflammatory response during acute phase response and prevent thrombosis by regulating the body immune system in a cohort study of 205 patients of KD (<xref rid="bib0122" ref-type="bibr">Wang&#x000a0;and Feng,&#x000a0;2002</xref>). Based on the above clinical observation, TCMs may act as an effective adjunct treatment to KD via shortening the disease duration and reducing the symptoms of the disease with less adverse side effects (<xref rid="bib0069" ref-type="bibr">Liu,&#x000a0;2017</xref>; <xref rid="bib0122" ref-type="bibr">Wang&#x000a0;and Feng,&#x000a0;2002</xref>; <xref rid="bib0124" ref-type="bibr">Wang,&#x000a0;2011</xref>).</p><p id="para0054">Based on the above observation, selected herbal chemicals which possess potent anti-inflammatory or immunoregulatory effects are hereby proposed as the potential remedies for the treatment of KD (<xref rid="fig0002" ref-type="fig">Fig. B</xref>
). For example, by interlinking the genetic susceptibility of KD to the traditional clinical applications and modern pharmacological actions of selected natural products, a list of potential herbal candidates for treating KD was proposed as shown in <xref rid="tbl0006" ref-type="table">Table&#x000a0;F</xref>
. By targeting the 3 potential KD genes such as TLR4, CASP3 and CD40, several potential effective single components derived from natural plants are suggested. For example, kaempferol derived from <italic>Kaempferia galanga L.</italic> may work as a novel therapeutic agent for KD via decreasing the expression level of CD40 in the bronchoalveolar lavage fluid cells (<xref rid="bib0077" ref-type="bibr">Medeiros&#x000a0;et&#x000a0;al., 2009</xref>). Quercetin derived from <italic>Fagopyrum tataricum (L.) Gaertn</italic> or oaks species can decrease the level of CD40 in cervical carcinoma cells and facilitate cytotoxic T lymphocyte responses (<xref rid="bib0027" ref-type="bibr">Hill&#x000a0;et&#x000a0;al., 2005</xref>). Similarly, emodin derived from <italic>Rheum rhabarbarum L., Rhamnus dahurica Pall</italic> (bark), and <italic>Reynoutria japonica Houtt</italic> (rhizome and root) may also be used for treating KD via its ability in decreasing both CASP3 and TNF-&#x003b1; level, and inhibiting NF-&#x003ba;B activation (<xref rid="bib0129" ref-type="bibr">Wu&#x000a0;et&#x000a0;al., 2007</xref>). For targeting TLR4 gene, several natural compounds are suggested for future investigation. For example, cryptotanshinone derived from <italic>Salvia miltiorrhiza Bunge</italic> can decrease the expression of TLR4 in Caco-2 cells stimulated by LPS, suggesting that cryptotanshinone may possess anti-inflammatory property via inhibition of NF-&#x003ba;B signaling pathway and decreased expression of TLR4. Zerumbone derived from <italic>Zingiber zerumbet (L.) Smith</italic> (rhizome) is a monocyclic sesquiterpenoid, which can reduce the level of pro-inflammatory cytokines such as TNF-&#x003b1; and decrease the upregulated protein level of TLR4 and NF-&#x003ba;B p-p65 for possessing the anti-inflammatory activities (<xref rid="bib0123" ref-type="bibr">Wang&#x000a0;et&#x000a0;al., 2019</xref>). Leng et&#x000a0;al. showed that astragaloside IV derived from <italic>Astragalus propinquus Schischkin</italic> (root) can decrease the expression of TLR4 and NF-&#x003ba;B p65 both <italic>in vivo</italic> and <italic>in vitro</italic>, and significantly improved the aortic endothelial function (<xref rid="bib0064" ref-type="bibr">Leng&#x000a0;et&#x000a0;al., 2018</xref>), suggesting the potential use of herbal chemicals for treating KD.<fig id="fig0002"><label>Fig. B</label><caption><p>Suggested possible adjuvant herbal therapies for KD. Schematic diagram showing the proposed use of herbal medicines as adjuvant therapy for KD, by targeting our 3 proposed enriched susceptibility genes to KD. (Red frame: TCMs targeting the gene CASP3; Blue frame: TCMs targeting the gene TLR4; Yellow frame: TCMs targeting the gene CD40), or targeting effectively on the immune and inflammatory system (Green frame: TCMs decoction for anti-inflammatory and immune regulation).</p></caption><alt-text id="alt0002">Fig. B</alt-text><graphic xlink:href="gr2_lrg"/></fig><table-wrap position="float" id="tbl0006"><label>Table F</label><caption><p>Suggested list of herbal medicines for pharmacological or clinical efficacy evaluation as KD adjuvant treatment remedies, based on their immunoregulatory and anti-inflammatory effects, or their abilites in targeting susceptibility genes to KD.</p></caption><alt-text id="alt0008">Table F</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top">Natural herbal compounds or extracts</th><th valign="top">Source</th><th valign="top">Proposed pharmacological mechanisms beneficial for targeting KD or its related genes</th><th valign="top">References</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top">Herbal chemicals targeting CD40 regulation</td></tr><tr><td valign="top">Kaempferol</td><td valign="top"><italic>Kaempferia galanga L.</italic> (rhizome)</td><td valign="top">Decreased CD40 expression level in the bronchoalveolar lavage fluid cells</td><td valign="top"><xref rid="bib0077" ref-type="bibr">Medeiros&#x000a0;et&#x000a0;al.,&#x000a0;2009</xref></td></tr><tr><td valign="top">Luteolin</td><td valign="top"><italic>Lonicera japonica Thunb</italic> (flower)<italic>, Perilla frutescens (L.) Britton</italic> (fruit)</td><td valign="top">Suppressed interferon-&#x003b3; and decreased CD40 expression</td><td valign="top"><xref rid="bib0099" ref-type="bibr">Rezai-Zadeh&#x000a0;et&#x000a0;al.,&#x000a0;2008</xref></td></tr><tr><td valign="top">Curcumin</td><td valign="top"><italic>Curcuma longa L.</italic> (rhizomes)</td><td valign="top">Decreased the level of CD40; modulated the Janus kinase/signal transducer and activator of transcription/suppressor of cytokine signaling pathway</td><td valign="top"><xref rid="bib0137" ref-type="bibr">Zhao&#x000a0;et&#x000a0;al.,&#x000a0;2016</xref></td></tr><tr><td valign="top">Quercetin</td><td valign="top"><italic>Fagopyrum tataricum (L.) Gaertn</italic> (root), <italic>oaks species</italic> and <italic>Quercus robur L.</italic> (bark)</td><td valign="top">Decreased the level of CD40 in cervical carcinoma cells; facilitated cytotoxic T lymphocyte responses and augmented chemotherapy-induced apoptosis</td><td valign="top"><xref rid="bib0027" ref-type="bibr">Hill&#x000a0;et&#x000a0;al.,&#x000a0;2005</xref></td></tr><tr><td colspan="4" align="left" valign="top">Herbal chemicals targeting CASP3</td></tr><tr><td valign="top">Crocin</td><td valign="top"><italic>Crocus sativus L.</italic> (stigma)</td><td valign="top">Decreased diazinon induced caspase-mediated apoptosis (CASP9 and CASP3)</td><td valign="top"><xref rid="bib0097" ref-type="bibr">Razavi&#x000a0;et&#x000a0;al.,&#x000a0;2016</xref></td></tr><tr><td valign="top">Epigallocatechin gallate</td><td valign="top"><italic>Camellia sinensis (L.)O.Kuntze</italic> (leaf)</td><td valign="top">Decreased CASP12 and CASP3 expression, and inhibited endoplasmic reticulum stress-associated neuronal apoptosis</td><td valign="top"><xref rid="bib0019" ref-type="bibr">Du&#x000a0;et&#x000a0;al.,&#x000a0;2018</xref></td></tr><tr><td valign="top">Emodin</td><td valign="top"><italic>Rheum rhabarbarum L.</italic> (rhizome)<italic>, Rhamnus dahurica Pall</italic> (bark), and <italic>Reynoutria japonica Houtt.</italic> (rhizome and root)</td><td valign="top">Inhibited CASP3 and NF-&#x003ba;B activation in local ischemic myocardium</td><td valign="top"><xref rid="bib0129" ref-type="bibr">Wu&#x000a0;et&#x000a0;al.,&#x000a0;2007</xref></td></tr><tr><td colspan="4" align="left" valign="top">Herbal chemicals targeting TLR4</td></tr><tr><td valign="top">Astragaloside IV</td><td valign="top"><italic>Astragalus propinquus Schischkin</italic> (root)</td><td valign="top">Decreased the expression of TLR4 and NF-&#x003ba;B p65 <italic>in vitro</italic> and <italic>in vivo</italic>, inhibited the NF-&#x003ba;B/TLR4 signaling pathway</td><td valign="top"><xref rid="bib0064" ref-type="bibr">Leng&#x000a0;et&#x000a0;al.,&#x000a0;2018</xref></td></tr><tr><td valign="top">Cannabidiol</td><td valign="top"><italic>Cannabis sativa L.</italic></td><td valign="top">Inhibited TLR4 and activation of NF-&#x003ba;B signaling pathway</td><td valign="top"><xref rid="bib0075" ref-type="bibr">Majdi,&#x000a0;2019</xref></td></tr><tr><td valign="top">Pinocembrin</td><td valign="top"><italic>Colla Apis</italic> and <italic>Boesenbergia rotunda (L.) Mansf.</italic> (rhizome)</td><td valign="top">Decreased M1-related cytokines and markers (IL-1&#x003b2;, IL-6, TNF-&#x003b1;, and inducible nitric oxide synthase), NF-&#x003ba;B activation, and TLR4 expression</td><td valign="top"><xref rid="bib0056" ref-type="bibr">Lan&#x000a0;et&#x000a0;al.,&#x000a0;2017</xref></td></tr><tr><td valign="top">Tetramethylpyrazine</td><td valign="top"><italic>Ligusticum striatum DC</italic> (rhizome)</td><td valign="top">Inhibited the TLR4-NF-&#x003ba;B-NLRP3 signaling pathway in the brain</td><td valign="top"><xref rid="bib0021" ref-type="bibr">Fu&#x000a0;et&#x000a0;al.,&#x000a0;2019</xref></td></tr><tr><td valign="top">Cryptotanshinone</td><td valign="top"><italic>Salvia miltiorrhiza Bunge</italic> (root)</td><td valign="top">Anti-inflammatory property by inhibiting NF-&#x003ba;B signaling pathway and decreased TLR4 expression</td><td valign="top"><xref rid="bib0010" ref-type="bibr">Cao&#x000a0;et&#x000a0;al.,&#x000a0;2018</xref></td></tr><tr><td valign="top">Zerumbone</td><td valign="top"><italic>Zingiber zerumbet (L.) Smith</italic> (rhizome)</td><td valign="top">Reduced the protein level of TLR4 and anti-inflammatory activities by the TLR4/NF-&#x003ba;B signaling pathway</td><td valign="top"><xref rid="bib0123" ref-type="bibr">Wang&#x000a0;et&#x000a0;al.,&#x000a0;2019</xref></td></tr><tr><td valign="top">Glycyrrhizic acid</td><td valign="top"><italic>Glycyrrhiza uralensis Fisch</italic> (root)</td><td valign="top">Reduced TLR4 expression related to neuro-inflammation</td><td valign="top"><xref rid="bib0070" ref-type="bibr">Liu et&#x000a0;al., 2019</xref></td></tr><tr><td valign="top">Herbal decoction</td><td valign="top">Herbal composition</td><td valign="top">Pharmacological actions, mechanisms or signaling pathways</td><td valign="top">References</td></tr><tr><td colspan="4" align="left" valign="top">Herbal chemicals with anti-inflammatory and immune regulation function</td></tr><tr><td valign="top">Xiongshao Capsule</td><td valign="top"><italic>Ligusticum striatum DC</italic> and <italic>Paeonia anomala L.</italic> (root)</td><td valign="top">Reduced the level of total cholesterol, free cholesterol and myeloperoxidase, protected the anti-inflammatory function of high-density lipoprotein</td><td valign="top"><xref rid="bib0136" ref-type="bibr">Zhang&#x000a0;et&#x000a0;al.,&#x000a0;2017</xref></td></tr><tr><td valign="top">Qishen Granules</td><td valign="top"><italic>Astragalus propinquus Schischkin and Codonopsis pilosula Franch.</italic> (root)</td><td valign="top">Inhibited inflammation through targeting the TNF-&#x003b1;-NF-&#x003ba;B and IL-6-Janus kinase2-signal transducer and activator of transcription3 signaling pathways</td><td valign="top"><xref rid="bib0065" ref-type="bibr">Li&#x000a0;et&#x000a0;al.,&#x000a0;2016</xref></td></tr><tr><td valign="top">Dan-Shen-Yin</td><td valign="top"><italic>Salvia miltiorrhiza Bunge, Santalum album L.</italic> (Lignum) <italic>and Amomum villosum Lour</italic> (fruit)</td><td valign="top">Reduced the level of inflammatory factors (TNF-&#x003b1; and IL-6) and scavenged free radicals through enhancing antioxidant defense enzymes</td><td valign="top"><xref rid="bib0130" ref-type="bibr">Yan&#x000a0;et&#x000a0;al.,&#x000a0;2012</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec0015"><title>Conclusion and perspectives</title><p id="para0055">Although there were regional and seasonal variation in the epidemiology of KD, the general trend in the incidence rate of KD is increasing worldwide. With the increasing number of cases in KD, the clinical diagnostic guidelines are constantly being updated to classify different types of KD. Although literatures have attributed the pathogenesis of KD to different factors such as regional and ethnic disparities, dietary and environmental factors, infectious agents, immuoregulatory and inflammatory responses, or genetic susceptibility, there is still a lack of a conclusive or integrative summary to confirm the etiology of KD. In fact, KD is classified as a self-limiting acute childhood disease, which is nowadays considered as one of the possible causative reasons for the development of coronary artery disease in adult, therefore, early diagnosis by using high-end technology or identification of specific clinical KD markers deserve our further elucidation. KD is most commonly considered as an immune disease, however, via candidate genes and genome-wide association studies of KD, various genetic factors related to both immune and inflammatory system, which finally contributed to disease susceptibility were discovered. Through bioinformatics analysis, our current study has identified 3 most enriched genes including TLR4, CASP3 and CD40, which are highly correlated to the pathophysiology of KD.</p><p id="para0056">At present, while the combination of IVIG and AAS is the standard therapy adopted in clinical practice worldwide, numerous KD cases were reported to be IVIG resistant. Besides, the possible risk of getting RS after prescription of AAS in children also worth our further identification of adjuvant therapy for KD. In this review, the use of herbal therapy as adjuvant therapy for KD were therefore proposed. While some of the herbal decoctions were suggested for prescription due to their traditional usage in treating KD, herbal chemicals which targeting not only on the immune and inflammatory system, but also the susceptibility genes to KD, were also recommended for further pharmacological or clinical evaluation. With the more advanced technology in modern pharmacological research, it is anticipated that novel therapeutic remedies targeting specific clinical markers of KD could be developed for accurate diagnosis and treatment of the disease.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="para0057">All authors declare no conflict of interest.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Abdin</surname><given-names>A.</given-names></name><name><surname>Sarhan</surname><given-names>N.</given-names></name></person-group><article-title>Resveratrol protects against experimental induced Reye&#x02019;s syndrome by prohibition of oxidative stress and restoration of complex I activity</article-title><source>Can. J. Physiol. Pharmacol.</source><volume>92</volume><year>2014</year><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="pmid">25162205</pub-id></element-citation></ref><ref id="bib0002"><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Ayusawa</surname><given-names>M.</given-names></name><name><surname>Sonobe</surname><given-names>T.</given-names></name><name><surname>Uemura</surname><given-names>S.</given-names></name><name><surname>Ogawa</surname><given-names>S.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Kiyosawa</surname><given-names>N.</given-names></name><name><surname>Ishii</surname><given-names>M.</given-names></name><name><surname>Harada</surname><given-names>K.</given-names></name></person-group><article-title>Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)</article-title><source>Pediatr. Int.</source><volume>47</volume><year>2005</year><fpage>232</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">15771703</pub-id></element-citation></ref><ref id="bib0003"><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Baoshen</surname><given-names>W.</given-names></name></person-group><article-title>Therapeutic effect of integrated traditional Chinese and Western medicine on Kawasaki disease</article-title><source>World Latest Med. Inf.</source><volume>18</volume><year>2018</year></element-citation></ref><ref id="bib0004"><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Belay</surname><given-names>E.D.</given-names></name><name><surname>Bresee</surname><given-names>J.S.</given-names></name><name><surname>Holman</surname><given-names>R.C.</given-names></name><name><surname>Khan</surname><given-names>A.S.</given-names></name><name><surname>Shahriari</surname><given-names>A.</given-names></name><name><surname>Schonberger</surname><given-names>L.B.</given-names></name></person-group><article-title>Reye&#x02019;s syndrome in the United States from 1981 through 1997</article-title><source>N. Engl. J. Med.</source><volume>340</volume><year>1999</year><fpage>1377</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">10228187</pub-id></element-citation></ref><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Broderick</surname><given-names>L.</given-names></name><name><surname>Tremoulet</surname><given-names>A.H.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Bastian</surname><given-names>J.F.</given-names></name><name><surname>Hoffman</surname><given-names>H.M.</given-names></name></person-group><article-title>Recurrent fever syndromes in patients after recovery from Kawasaki syndrome</article-title><source>Pediatrics</source><volume>127</volume><year>2011</year><fpage>E489</fpage><lpage>E493</lpage><pub-id pub-id-type="pmid">21220401</pub-id></element-citation></ref><ref id="bib0006"><element-citation publication-type="journal" id="sbref0006"><person-group person-group-type="author"><name><surname>Burgner</surname><given-names>D.</given-names></name><name><surname>Davila</surname><given-names>S.</given-names></name><name><surname>Breunis</surname><given-names>W.B.</given-names></name><name><surname>Ng</surname><given-names>S.B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Bonnard</surname><given-names>C.</given-names></name><name><surname>Ling</surname><given-names>L.</given-names></name><name><surname>Wright</surname><given-names>V.J.</given-names></name><name><surname>Thalamuthu</surname><given-names>A.</given-names></name><name><surname>Odam</surname><given-names>M.</given-names></name><name><surname>Shimizu</surname><given-names>C.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Levin</surname><given-names>M.</given-names></name><name><surname>Kuijpers</surname><given-names>T.W.</given-names></name><name><surname>Hibberd</surname><given-names>M.L.</given-names></name><name><surname>Int Kawasaki Dis Genetics</surname><given-names>C.</given-names></name></person-group><article-title>A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease</article-title><source>PLoS Genet.</source><volume>5</volume><year>2009</year></element-citation></ref><ref id="bib0007"><element-citation publication-type="journal" id="sbref0007"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Glode</surname><given-names>M.P.</given-names></name></person-group><article-title>Kawasaki syndrome</article-title><source>Lancet</source><volume>364</volume><year>2004</year><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">15302199</pub-id></element-citation></ref><ref id="bib0008"><element-citation publication-type="journal" id="sbref0008"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Kushner</surname><given-names>H.I.</given-names></name><name><surname>Bastian</surname><given-names>J.F.</given-names></name><name><surname>Shike</surname><given-names>H.</given-names></name><name><surname>Shimizu</surname><given-names>C.</given-names></name><name><surname>Matsubara</surname><given-names>T.</given-names></name><name><surname>Turner</surname><given-names>C.L.</given-names></name></person-group><article-title>Kawasaki disease: a brief history</article-title><source>Pediatrics</source><volume>106</volume><year>2000</year><fpage>8</fpage></element-citation></ref><ref id="bib0009"><element-citation publication-type="journal" id="sbref0009"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>W.S.</given-names></name><name><surname>Moore</surname><given-names>J.H.</given-names></name></person-group><article-title>Chapter 11: Genome-wide association studies</article-title><source>PLoS Comput. Biol.</source><volume>8</volume><year>2012</year><object-id pub-id-type="publisher-id">e1002822</object-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>S.G.</given-names></name><name><surname>Chen</surname><given-names>R.J.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Lin</surname><given-names>L.M.</given-names></name><name><surname>Xia</surname><given-names>X.P.</given-names></name></person-group><article-title>Cryptotanshinone inhibits prostaglandin E2 production and COX-2 expression via suppression of TLR4/NF-kappa B signaling pathway in LPS-stimulated Caco-2 cells</article-title><source>Microb. Pathog.</source><volume>116</volume><year>2018</year><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">29353005</pub-id></element-citation></ref><ref id="bib0011"><element-citation publication-type="journal" id="sbref0011"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L.Y.</given-names></name><name><surname>Lu</surname><given-names>C.Y.</given-names></name><name><surname>Shao</surname><given-names>P.L.</given-names></name><name><surname>Lee</surname><given-names>P.I.</given-names></name><name><surname>Lin</surname><given-names>M.T.</given-names></name><name><surname>Fan</surname><given-names>T.Y.</given-names></name><name><surname>Cheng</surname><given-names>A.L.</given-names></name><name><surname>Lee</surname><given-names>W.L.</given-names></name><name><surname>Hu</surname><given-names>J.J.</given-names></name><name><surname>Yeh</surname><given-names>S.J.</given-names></name><name><surname>Chang</surname><given-names>C.C.</given-names></name><name><surname>Chiang</surname><given-names>B.L.</given-names></name><name><surname>Wu</surname><given-names>M.H.</given-names></name><name><surname>Huang</surname><given-names>L.M.</given-names></name></person-group><article-title>Viral infections associated with Kawasaki disease</article-title><source>J. Formos. Med. Assoc.</source><volume>113</volume><year>2014</year><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">24495555</pub-id></element-citation></ref><ref id="bib0012"><element-citation publication-type="book" id="sbref0012"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>J.</given-names></name><name><surname>Arnold</surname><given-names>J.K.</given-names></name></person-group><chapter-title>Reye Syndrome, StatPearls</chapter-title><year>2020</year><publisher-name>StatPearls Publishing, StatPearls Publishing LLC.</publisher-name><publisher-loc>Treasure Island (FL)</publisher-loc></element-citation></ref><ref id="bib0013"><element-citation publication-type="journal" id="sbref0013"><person-group person-group-type="author"><name><surname>Chatzikyriakidou</surname><given-names>A.</given-names></name><name><surname>Aidinidou</surname><given-names>L.</given-names></name><name><surname>Giannopoulos</surname><given-names>A.</given-names></name><name><surname>Papadopoulou-Legbelou</surname><given-names>K.</given-names></name><name><surname>Kalinderi</surname><given-names>K.</given-names></name><name><surname>Fidani</surname><given-names>L.</given-names></name></person-group><article-title>Absence of association of FCGR2A gene polymorphism rs1801274 with Kawasaki disease in Greek patients</article-title><source>Cardiol. Young</source><volume>25</volume><year>2015</year><fpage>681</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">24775607</pub-id></element-citation></ref><ref id="bib0014"><element-citation publication-type="journal" id="sbref0014"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Yin</surname><given-names>J.M.</given-names></name><name><surname>Du</surname><given-names>Z.D.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>H.M.</given-names></name></person-group><article-title>Qing re liang xue decoction alleviates hypercoagulability in Kawasaki disease</article-title><source>Evid.-Based Complement. Altern. Med.</source><year>2015</year></element-citation></ref><ref id="bib0015"><element-citation publication-type="book" id="sbref0015"><person-group person-group-type="author"><name><surname>Chornomydz</surname><given-names>I.</given-names></name><name><surname>Boyarchuk</surname><given-names>O.</given-names></name><name><surname>Chornomydz</surname><given-names>A.</given-names></name></person-group><chapter-title>Reye (Ray's) Syndrome: a Problem Everyone Should Remember</chapter-title><year>2017</year><publisher-name>Georgian Med News</publisher-name><fpage>110</fpage><lpage>118</lpage></element-citation></ref><ref id="bib0016"><element-citation publication-type="journal" id="sbref0016"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>L.B.</given-names></name><name><surname>Tjajadi</surname><given-names>M.S.</given-names></name><name><surname>Walford</surname><given-names>H.H.</given-names></name><name><surname>Jimenez-Fernandez</surname><given-names>S.</given-names></name><name><surname>Trofimenko</surname><given-names>V.</given-names></name><name><surname>Fick</surname><given-names>D.B.</given-names></name><name><surname>Phan</surname><given-names>H.A.L.</given-names></name><name><surname>Linz</surname><given-names>P.E.</given-names></name><name><surname>Nayak</surname><given-names>K.</given-names></name><name><surname>Kahn</surname><given-names>A.M.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Gordon</surname><given-names>J.B.</given-names></name></person-group><article-title>Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia</article-title><source>Circulation</source><volume>125</volume><year>2012</year><fpage>2447</fpage><lpage>2453</lpage><pub-id pub-id-type="pmid">22595319</pub-id></element-citation></ref><ref id="bib0017"><element-citation publication-type="journal" id="sbref0017"><person-group person-group-type="author"><name><surname>Denby</surname><given-names>K.J.</given-names></name><name><surname>Clark</surname><given-names>D.E.</given-names></name><name><surname>Markham</surname><given-names>L.W.</given-names></name></person-group><article-title>Management of Kawasaki disease in adults</article-title><source>Heart</source><volume>103</volume><year>2017</year><fpage>1760</fpage><lpage>1769</lpage><pub-id pub-id-type="pmid">28751537</pub-id></element-citation></ref><ref id="bib0018"><element-citation publication-type="journal" id="sbref0018"><person-group person-group-type="author"><name><surname>Dimitriades</surname><given-names>V.R.</given-names></name><name><surname>Brown</surname><given-names>A.G.</given-names></name><name><surname>Gedalia</surname><given-names>A.</given-names></name></person-group><article-title>Kawasaki Disease: pathophysiology, clinical manifestations, and management</article-title><source>Curr. Rheumatol. Rep.</source><volume>16</volume><year>2014</year></element-citation></ref><ref id="bib0019"><element-citation publication-type="journal" id="sbref0019"><person-group person-group-type="author"><name><surname>Du</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>M.Y.</given-names></name><name><surname>Zhong</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>W.F.</given-names></name><name><surname>Xiao</surname><given-names>Q.H.</given-names></name><name><surname>Wen</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wei</surname><given-names>M.J.</given-names></name></person-group><article-title>Epigallocatechin gallate reduces amyloid beta-induced neurotoxicity via inhibiting endoplasmic reticulum stress-mediated apoptosis</article-title><source>Mol. Nutr. Food Res.</source><volume>62</volume><year>2018</year></element-citation></ref><ref id="bib0020"><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>J.N.</given-names></name><name><surname>Tan</surname><given-names>L.C.</given-names></name><name><surname>Irwan</surname><given-names>I.D.</given-names></name><name><surname>Au</surname><given-names>W.L.</given-names></name><name><surname>Low</surname><given-names>H.Q.</given-names></name><name><surname>Prakash</surname><given-names>K.M.</given-names></name><name><surname>Ahmad-Annuar</surname><given-names>A.</given-names></name><name><surname>Bei</surname><given-names>J.</given-names></name><name><surname>Chan</surname><given-names>A.Y.</given-names></name><name><surname>Chen</surname><given-names>C.M.</given-names></name><name><surname>Chen</surname><given-names>Y.C.</given-names></name><name><surname>Chung</surname><given-names>S.J.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Lim</surname><given-names>S.Y.</given-names></name><name><surname>Mok</surname><given-names>V.</given-names></name><name><surname>Pang</surname><given-names>H.</given-names></name><name><surname>Pei</surname><given-names>Z.</given-names></name><name><surname>Peng</surname><given-names>R.</given-names></name><name><surname>Shang</surname><given-names>H.F.</given-names></name><name><surname>Song</surname><given-names>K.</given-names></name><name><surname>Tan</surname><given-names>A.H.</given-names></name><name><surname>Wu</surname><given-names>Y.R.</given-names></name><name><surname>Aung</surname><given-names>T.</given-names></name><name><surname>Cheng</surname><given-names>C.Y.</given-names></name><name><surname>Chew</surname><given-names>F.T.</given-names></name><name><surname>Chew</surname><given-names>S.H.</given-names></name><name><surname>Chong</surname><given-names>S.A.</given-names></name><name><surname>Ebstein</surname><given-names>R.P.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Saw</surname><given-names>S.M.</given-names></name><name><surname>Seow</surname><given-names>A.</given-names></name><name><surname>Subramaniam</surname><given-names>M.</given-names></name><name><surname>Tai</surname><given-names>E.S.</given-names></name><name><surname>Vithana</surname><given-names>E.N.</given-names></name><name><surname>Wong</surname><given-names>T.Y.</given-names></name><name><surname>Heng</surname><given-names>K.K.</given-names></name><name><surname>Meah</surname><given-names>W.Y.</given-names></name><name><surname>Khor</surname><given-names>C.C.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Tan</surname><given-names>E.K.</given-names></name></person-group><article-title>Genome-wide association study of Parkinson&#x02019;s disease in East Asians</article-title><source>Hum. Mol. Genet.</source><volume>26</volume><year>2017</year><fpage>226</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">28011712</pub-id></element-citation></ref><ref id="bib0021"><element-citation publication-type="journal" id="sbref0021"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>S.N.</given-names></name><name><surname>Wang</surname><given-names>J.T.</given-names></name><name><surname>Hao</surname><given-names>C.G.</given-names></name><name><surname>Dang</surname><given-names>H.H.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Tetramethylpyrazine ameliorates depression by inhibiting TLR4-NLRP3 inflammasome signal pathway in mice</article-title><source>Psychopharmacology</source><volume>236</volume><year>2019</year><fpage>2173</fpage><lpage>2185</lpage><pub-id pub-id-type="pmid">30847567</pub-id></element-citation></ref><ref id="bib0022"><element-citation publication-type="journal" id="sbref0022"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>S.</given-names></name><name><surname>Ito</surname><given-names>S.</given-names></name><name><surname>Fujiwara</surname><given-names>M.</given-names></name><name><surname>Abe</surname><given-names>J.</given-names></name><name><surname>Hanaoka</surname><given-names>N.</given-names></name><name><surname>Fujimoto</surname><given-names>T.</given-names></name><name><surname>Katsumori</surname><given-names>H.</given-names></name></person-group><article-title>Simultaneous development of Kawasaki disease following acute human adenovirus infection in monozygotic twins: a case report</article-title><source>Pediatr. Rheumatol.</source><volume>15</volume><year>2017</year><fpage>5</fpage></element-citation></ref><ref id="bib0023"><element-citation publication-type="journal" id="sbref0023"><person-group person-group-type="author"><name><surname>Gamez&#x02010;Gonzalez</surname><given-names>L.B.</given-names></name><name><surname>Moribe&#x02010;Quintero</surname><given-names>I.</given-names></name><name><surname>Cisneros&#x02010;Castolo</surname><given-names>M.</given-names></name><name><surname>Varela&#x02010;Ortiz</surname><given-names>J.</given-names></name><name><surname>Mu&#x000f1;oz&#x02010;Ram&#x000ed;rez</surname><given-names>M.</given-names></name><name><surname>Garrido&#x02010;Garc&#x000ed;a</surname><given-names>M.</given-names></name><name><surname>Yamazaki&#x02010;Nakashimada</surname><given-names>M.</given-names></name></person-group><article-title>Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease</article-title><source>Pediatr. Int.</source><volume>60</volume><year>2018</year><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">29888440</pub-id></element-citation></ref><ref id="bib0024"><element-citation publication-type="journal" id="sbref0024"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>S.</given-names></name><name><surname>Seo</surname><given-names>G.H.</given-names></name><name><surname>Kim</surname><given-names>K.Y.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name></person-group><article-title>Epidemiologic study on Kawasaki Disease in Korea, 2007&#x02013;2014: based on health insurance review &#x00026; assessment service claims</article-title><source>J. Korean Med. Sci.</source><volume>31</volume><year>2016</year><fpage>1445</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">27510389</pub-id></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Rhim</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name></person-group><article-title>Correlation between elevated platelet count and immunoglobulin levels in the early convalescent stage of Kawasaki disease</article-title><source>Medicine</source><volume>96</volume><year>2017</year><fpage>e7583</fpage><pub-id pub-id-type="pmid">28723797</pub-id></element-citation></ref><ref id="bib0026"><element-citation publication-type="journal" id="sbref0026"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>T.</given-names></name><name><surname>Nakashima</surname><given-names>Y.</given-names></name><name><surname>Sakai</surname><given-names>Y.</given-names></name><name><surname>Nishio</surname><given-names>H.</given-names></name><name><surname>Motomura</surname><given-names>Y.</given-names></name><name><surname>Yamasaki</surname><given-names>S.</given-names></name></person-group><article-title>Kawasaki disease: a matter of innate immunity</article-title><source>Clin. Exp. Immunol.</source><volume>186</volume><year>2016</year><fpage>134</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">27342882</pub-id></element-citation></ref><ref id="bib0027"><element-citation publication-type="journal" id="sbref0027"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>S.C.</given-names></name><name><surname>Youde</surname><given-names>S.J.</given-names></name><name><surname>Man</surname><given-names>S.</given-names></name><name><surname>Teale</surname><given-names>G.R.</given-names></name><name><surname>Baxendale</surname><given-names>A.J.</given-names></name><name><surname>Hislop</surname><given-names>A.</given-names></name><name><surname>Davies</surname><given-names>C.C.</given-names></name><name><surname>Luesley</surname><given-names>D.M.</given-names></name><name><surname>Blom</surname><given-names>A.M.</given-names></name><name><surname>Rickinson</surname><given-names>A.B.</given-names></name></person-group><article-title>Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis</article-title><source>J. Immunol.</source><volume>174</volume><year>2005</year><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">15611226</pub-id></element-citation></ref><ref id="bib0028"><element-citation publication-type="journal" id="sbref0028"><person-group person-group-type="author"><name><surname>Hokosaki</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Nishizawa</surname><given-names>T.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Imagawa</surname><given-names>T.</given-names></name><name><surname>Iwamoto</surname><given-names>M.</given-names></name><name><surname>Yokota</surname><given-names>S.</given-names></name></person-group><article-title>Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease</article-title><source>Pediatr. Int.</source><volume>54</volume><year>2012</year><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">22004042</pub-id></element-citation></ref><ref id="bib0029"><element-citation publication-type="journal" id="sbref0029"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D.W.</given-names></name><name><surname>Sherman</surname><given-names>B.T.</given-names></name><name><surname>Lempicki</surname><given-names>R.A.</given-names></name></person-group><article-title>Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists</article-title><source>Nucl. Acids Res.</source><volume>37</volume><year>2009</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">19033363</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="book" id="sbref0030"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>F.-C.</given-names></name><name><surname>Kuo</surname><given-names>H.-C.</given-names></name><name><surname>Huang</surname><given-names>Y.-H.</given-names></name><name><surname>Yu</surname><given-names>H.-R.</given-names></name><name><surname>Li</surname><given-names>S.-C.</given-names></name><name><surname>Kuo</surname><given-names>H.-C.</given-names></name></person-group><chapter-title>Anti-Inflammatory Effect of Resveratrol in Human Coronary Arterial Endothelial Cells Via Induction of Autophagy: Implication for the Treatment of Kawasaki Disease</chapter-title><year>2017</year><publisher-name>BioMed Central Ltd.</publisher-name></element-citation></ref><ref id="bib0031"><element-citation publication-type="journal" id="sbref0031"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>J.Y.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Rhim</surname><given-names>J.W.</given-names></name><name><surname>Youn</surname><given-names>Y.S.</given-names></name><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Burgner</surname><given-names>D.</given-names></name></person-group><article-title>Assessment of intravenous immunoglobulin non-responders in Kawasaki disease</article-title><source>Arch. Dis. Child.</source><volume>96</volume><year>2011</year><fpage>1088</fpage><lpage>1090</lpage><pub-id pub-id-type="pmid">20551193</pub-id></element-citation></ref><ref id="bib0032"><element-citation publication-type="journal" id="sbref0032"><person-group person-group-type="author"><name><surname>Jaggi</surname><given-names>P.</given-names></name><name><surname>Kajon</surname><given-names>A.E.</given-names></name><name><surname>Mejias</surname><given-names>A.</given-names></name><name><surname>Ramilo</surname><given-names>O.</given-names></name><name><surname>Leber</surname><given-names>A.</given-names></name></person-group><article-title>Human adenovirus infection in Kawasaki disease: a confounding bystander?</article-title><source>Clin. Infect. Dis.</source><volume>56</volume><year>2013</year><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">23011145</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal" id="optfNTGiGAXGE"><person-group person-group-type="author"><name><surname>Jane</surname><given-names>W</given-names><suffix>Newburger</suffix></name><name><surname>Kathryn</surname><given-names>A.Taubert</given-names></name><name><surname>Stanford</surname><given-names>T.Shulman</given-names></name><name><surname>Anne</surname><given-names>H.Rowley</given-names></name><name><surname>Michael</surname><given-names>H.Gewitz</given-names></name><name><surname>Masato</surname><given-names>Takahashi</given-names></name><name><surname>Brian</surname><given-names>W.Mccrindle</given-names></name></person-group><article-title>Summary and Abstracts of the Seventh International Kawasaki Disease Symposium: December 4&#x02013;7, 2001, Hakone, Japan</article-title><source>Pediatr. Res.</source><volume>53</volume><issue>1</issue><year>2003</year><comment>153&#x02013;153</comment></element-citation></ref><ref id="bib0033"><element-citation publication-type="book" id="sbref0033"><person-group person-group-type="author"><name><surname>Japan</surname><given-names>K.D.A.o.</given-names></name></person-group><chapter-title>The 24th National Survey Results of Kawasaki Disease in Japan</chapter-title><year>2017</year><publisher-name>Autonomous medical university</publisher-name><publisher-loc>Japan</publisher-loc></element-citation></ref><ref id="bib0034"><element-citation publication-type="journal" id="sbref0034"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Y.X.</given-names></name><name><surname>Zhang</surname><given-names>H.Y.</given-names></name><name><surname>Lin</surname><given-names>S.X.</given-names></name></person-group><article-title>Single nucleotide polymorphism of FCGR2A gene in Han Chinese children with Kawasaki disease</article-title><source>Chin. J. Contemp. Pediatr.</source><volume>15</volume><year>2013</year><fpage>196</fpage><lpage>200</lpage></element-citation></ref><ref id="bib0035"><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zu</surname><given-names>Y.</given-names></name></person-group><article-title>The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease</article-title><source>Clin. Exp. Immunol.</source><volume>162</volume><year>2010</year><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">20718783</pub-id></element-citation></ref><ref id="bib0036"><element-citation publication-type="journal" id="sbref0036"><person-group person-group-type="author"><name><surname>Jordan-Villegas</surname><given-names>A.</given-names></name><name><surname>Chang</surname><given-names>M.L.</given-names></name><name><surname>Ramilo</surname><given-names>O.</given-names></name><name><surname>Mejias</surname><given-names>A.</given-names></name></person-group><article-title>Concomitant respiratory viral infections in children with Kawasaki disease</article-title><source>Pediatr. Infect. Dis. J.</source><volume>29</volume><year>2010</year><fpage>770</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">20354462</pub-id></element-citation></ref><ref id="bib0037"><element-citation publication-type="journal" id="sbref0037"><person-group person-group-type="author"><name><surname>Jung-Woo</surname><given-names>R.</given-names></name><name><surname>Hyun Mi</surname><given-names>K.</given-names></name><name><surname>Ji-Whan</surname><given-names>H.</given-names></name><name><surname>Kyung-Yil</surname><given-names>L.</given-names></name></person-group><article-title>A presumed etiology of Kawasaki disease based on epidemiological comparison with infectious or immune-mediated diseases</article-title><source>Front. Pediatr.</source><volume>7</volume><year>2019</year></element-citation></ref><ref id="bib0038"><element-citation publication-type="journal" id="sbref0038"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>C.R.</given-names></name><name><surname>Chen</surname><given-names>W.T.</given-names></name><name><surname>Lin</surname><given-names>Y.T.</given-names></name><name><surname>Hwang</surname><given-names>B.F.</given-names></name></person-group><article-title>Ambient air pollutant exposures and hospitalization for Kawasaki disease in Taiwan: a case-crossover study (2000&#x02013;2010)</article-title><source>Environ. Health Perspect.</source><volume>125</volume><year>2017</year><fpage>670</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">27458717</pub-id></element-citation></ref><ref id="bib0039"><element-citation publication-type="journal" id="sbref0039"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T.</given-names></name></person-group><article-title>Pediatric acute febrile mucocutaneous lymph node syndrome with characteristic desquamation of fingers and toes: my clinical observation of fifty cases</article-title><source>Pediatr. Infect. Dis. J.</source><volume>21</volume><year>2002</year><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">11791090</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal" id="opth1SNWENhpS"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>Tomisaku</given-names></name><name><surname>Kosaki</surname><given-names>Fumio</given-names></name><name><surname>Okawa</surname><given-names>Sumio</given-names></name><name><surname>Shigematsu</surname><given-names>Itsuzo</given-names></name><name><surname>Yanagawa</surname><given-names>Hiroshi</given-names></name></person-group><article-title>A New Infantile Acute Febrile Mucocutaneous Lymph Node Syndrome (MLNS) Prevailing in Japan</article-title><source>Pediatrics</source><volume>54</volume><issue>3</issue><year>1974</year><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">4153258</pub-id></element-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Khor</surname><given-names>C.C.</given-names></name><name><surname>Davila</surname><given-names>S.</given-names></name><name><surname>Breunis</surname><given-names>W.B.</given-names></name><name><surname>Lee</surname><given-names>Y.C.</given-names></name><name><surname>Shimizu</surname><given-names>C.</given-names></name><name><surname>Wright</surname><given-names>V.J.</given-names></name><name><surname>Yeung</surname><given-names>R.S.M.</given-names></name><name><surname>Tan</surname><given-names>D.E.K.</given-names></name><name><surname>Sim</surname><given-names>K.S.</given-names></name><name><surname>Wang</surname><given-names>J.J.</given-names></name><name><surname>Wong</surname><given-names>T.Y.</given-names></name><name><surname>Pang</surname><given-names>J.X.</given-names></name><name><surname>Mitchell</surname><given-names>P.</given-names></name><name><surname>Cimaz</surname><given-names>R.</given-names></name><name><surname>Dahdah</surname><given-names>N.</given-names></name><name><surname>Cheung</surname><given-names>Y.F.</given-names></name><name><surname>Huang</surname><given-names>G.Y.</given-names></name><name><surname>Yang</surname><given-names>W.L.</given-names></name><name><surname>Park</surname><given-names>I.S.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name><name><surname>Wu</surname><given-names>J.Y.</given-names></name><name><surname>Levin</surname><given-names>M.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Burgner</surname><given-names>D.</given-names></name><name><surname>Kuijpers</surname><given-names>T.W.</given-names></name><name><surname>Hibberd</surname><given-names>M.L.</given-names></name><name><surname>Lau</surname><given-names>Y.L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>X.J.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Yoo</surname><given-names>J.J.</given-names></name><name><surname>Hong</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>K.J.</given-names></name><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Park</surname><given-names>Y.M.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Ha</surname><given-names>K.S.</given-names></name><name><surname>Nam</surname><given-names>H.K.</given-names></name><name><surname>Byeon</surname><given-names>J.H.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Han</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Hwang</surname><given-names>J.Y.</given-names></name><name><surname>Rhim</surname><given-names>J.W.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Chang</surname><given-names>J.S.</given-names></name><name><surname>Tsai</surname><given-names>F.J.</given-names></name><name><surname>Liang</surname><given-names>C.D.</given-names></name><name><surname>Chen</surname><given-names>M.R.</given-names></name><name><surname>Chi</surname><given-names>H.</given-names></name><name><surname>Chiu</surname><given-names>N.C.</given-names></name><name><surname>Huang</surname><given-names>F.Y.</given-names></name><name><surname>Chang</surname><given-names>L.Y.</given-names></name><name><surname>Huang</surname><given-names>L.M.</given-names></name><name><surname>Kuo</surname><given-names>H.C.</given-names></name><name><surname>Huang</surname><given-names>K.P.</given-names></name><name><surname>Lee</surname><given-names>M.L.</given-names></name><name><surname>Hwang</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>Y.C.</given-names></name><name><surname>Lee</surname><given-names>P.C.</given-names></name><name><surname>Odam</surname><given-names>M.</given-names></name><name><surname>Christiansen</surname><given-names>F.T.</given-names></name><name><surname>Witt</surname><given-names>C.</given-names></name><name><surname>Goldwater</surname><given-names>P.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name><name><surname>Palasanthiran</surname><given-names>P.</given-names></name><name><surname>Ziegler</surname><given-names>J.</given-names></name><name><surname>Nissen</surname><given-names>M.</given-names></name><name><surname>Nourse</surname><given-names>C.</given-names></name><name><surname>Kuipers</surname><given-names>I.M.</given-names></name><name><surname>Ottenkamp</surname><given-names>J.J.</given-names></name><name><surname>Geissler</surname><given-names>J.</given-names></name><name><surname>Biezeveld</surname><given-names>M.</given-names></name><name><surname>Tacke</surname><given-names>C.</given-names></name><name><surname>Filippini</surname><given-names>L.</given-names></name><name><surname>Brogan</surname><given-names>P.</given-names></name><name><surname>Klein</surname><given-names>N.</given-names></name><name><surname>Shah</surname><given-names>V.</given-names></name><name><surname>Dillon</surname><given-names>M.</given-names></name><name><surname>Booy</surname><given-names>R.</given-names></name><name><surname>Shingadia</surname><given-names>D.</given-names></name><name><surname>Bose</surname><given-names>A.</given-names></name><name><surname>Mukasa</surname><given-names>T.</given-names></name><name><surname>Tulloh</surname><given-names>R.</given-names></name><name><surname>Michie</surname><given-names>C.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Baker</surname><given-names>A.L.</given-names></name><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Mason</surname><given-names>W.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Melish</surname><given-names>M.E.</given-names></name><name><surname>Tremoulet</surname><given-names>A.H.</given-names></name><name><surname>Viswanathan</surname><given-names>A.</given-names></name><name><surname>Rochtchina</surname><given-names>E.</given-names></name><name><surname>Attia</surname><given-names>J.</given-names></name><name><surname>Scott</surname><given-names>R.</given-names></name><name><surname>Holliday</surname><given-names>E.</given-names></name><name><surname>Harrap</surname><given-names>S.</given-names></name><name><surname>Hong Kong-Shanghai Kawasaki Dis</surname><given-names>G.</given-names></name><name><surname>Korean Kawasaki Dis Genetics</surname><given-names>C.</given-names></name><name><surname>Taiwan Kawasaki Dis Genetics</surname><given-names>C.</given-names></name><name><surname>Int Kawasaki Dis Genetics</surname><given-names>C.</given-names></name><name><surname>Consortiu</surname><given-names>U.S.K.D.G.</given-names></name><name><surname>Blue Mt Eye</surname><given-names>S.</given-names></name></person-group><article-title>Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease</article-title><source>Nat. Genet.</source><volume>43</volume><year>2011</year><fpage>1241</fpage><lpage>1246</lpage><pub-id pub-id-type="pmid">22081228</pub-id></element-citation></ref><ref id="bib0041"><element-citation publication-type="journal" id="sbref0041"><person-group person-group-type="author"><name><surname>Kil</surname><given-names>H.-R.</given-names></name><name><surname>Yu</surname><given-names>J.-W.</given-names></name><name><surname>Lee</surname><given-names>S.-C.</given-names></name><name><surname>Rhim</surname><given-names>J.-W.</given-names></name><name><surname>Lee</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea</article-title><source>Pediatr. Rheumatol. Online J.</source><volume>15</volume><year>2017</year><fpage>60</fpage><pub-id pub-id-type="pmid">28784161</pub-id></element-citation></ref><ref id="bib0042"><element-citation publication-type="journal" id="sbref0042"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>G.B.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Eun</surname><given-names>L.Y.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Yoon</surname><given-names>K.L.</given-names></name><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Choi</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name></person-group><article-title>Epidemiology and clinical features of Kawasaki disease in South Korea, 2012&#x02013;2014</article-title><source>Pediatr. Infect. Dis. J.</source><volume>36</volume><year>2017</year><fpage>482</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">27997519</pub-id></element-citation></ref><ref id="bib0043"><element-citation publication-type="journal" id="sbref0043"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.E.</given-names></name><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Han</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Park</surname><given-names>I.S.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name></person-group><article-title>Variations in the number of CCL3L1 gene copies and Kawasaki disease in Korean children</article-title><source>Pediatr. Cardiol.</source><volume>33</volume><year>2012</year><fpage>1259</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">22450355</pub-id></element-citation></ref><ref id="bib0044"><element-citation publication-type="journal" id="sbref0044"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.-J.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Yoon</surname><given-names>K.L.</given-names></name><name><surname>Lee</surname><given-names>K.-Y.</given-names></name><name><surname>Kil</surname><given-names>H.-R.</given-names></name><name><surname>Kim</surname><given-names>G.B.</given-names></name><name><surname>Han</surname><given-names>M.K.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Byeon</surname><given-names>J.H.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Lee</surname><given-names>J.-K.</given-names></name><name><surname>Korean Kawasaki Disease Genetics</surname><given-names>C.</given-names></name></person-group><article-title>Common variants in the CRP promoter are associated with a high C-reactive protein level in Kawasaki disease</article-title><source>Pediatr. Cardiol.</source><volume>36</volume><year>2015</year><fpage>438</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">25266886</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal" id="opt83jDGwKPqW"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.S.</given-names></name></person-group><article-title>Kawasaki disease</article-title><source>YONSEI MED J</source><volume>47</volume><issue>6</issue><year>2006</year><fpage>759</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">17191303</pub-id></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Ha</surname><given-names>K.S.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Han</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name><name><surname>Lee</surname><given-names>J.E.</given-names></name><name><surname>Shin</surname><given-names>E.S.</given-names></name><name><surname>Jang</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>Y.S.</given-names></name><name><surname>Kim</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Han</surname><given-names>B.G.</given-names></name><name><surname>Wu</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>K.J.</given-names></name><name><surname>Park</surname><given-names>Y.M.</given-names></name><name><surname>Seo</surname><given-names>E.J.</given-names></name><name><surname>Park</surname><given-names>I.S.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name></person-group><article-title>A genome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease</article-title><source>Hum. Genet.</source><volume>129</volume><year>2011</year><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">21221998</pub-id></element-citation></ref><ref id="bib0046"><element-citation publication-type="journal" id="sbref0046"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Han</surname><given-names>M.K.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Ha</surname><given-names>K.S.</given-names></name><name><surname>Hong</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>K.J.</given-names></name><name><surname>Park</surname><given-names>I.S.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name></person-group><article-title>Assessment of risk factors for Korean children with Kawasaki disease</article-title><source>Pediatr. Cardiol.</source><volume>33</volume><year>2012</year><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">22105492</pub-id></element-citation></ref><ref id="bib0047"><element-citation publication-type="journal" id="sbref0047"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Park</surname><given-names>Y.M.</given-names></name><name><surname>Yoon</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Seob Song</surname><given-names>M.</given-names></name><name><surname>Doo Lee</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>K.J.</given-names></name><name><surname>Park</surname><given-names>I.S.</given-names></name><name><surname>Nam</surname><given-names>H.K.</given-names></name><name><surname>Weon Yun</surname><given-names>S.</given-names></name><name><surname>Ki Han</surname><given-names>M.</given-names></name><name><surname>Mi Hong</surname><given-names>Y.</given-names></name><name><surname>Young Jang</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name></person-group><article-title>Identification of KCNN2 as a susceptibility locus for coronary artery aneurysms in Kawasaki disease using genome-wide association analysis</article-title><source>J. Hum. Genet.</source><volume>58</volume><year>2013</year><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">23677057</pub-id></element-citation></ref><ref id="bib0048"><element-citation publication-type="journal" id="sbref0048"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.J.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Yoon</surname><given-names>K.L.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Kil</surname><given-names>H.R.</given-names></name><name><surname>Kim</surname><given-names>G.B.</given-names></name><name><surname>Han</surname><given-names>M.K.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Ha</surname><given-names>K.S.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>T.A.</given-names></name><name><surname>Takahashi</surname><given-names>A.</given-names></name><name><surname>Kubo</surname><given-names>M.</given-names></name><name><surname>Tsunoda</surname><given-names>T.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Onouchi</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Lee</surname><given-names>J.K.</given-names></name></person-group><article-title>A genome-wide association analysis identifies NMNAT2 and HCP5 as susceptibility loci for Kawasaki disease</article-title><source>J. Hum. Genet.</source><volume>62</volume><year>2017</year><fpage>1023</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">28855716</pub-id></element-citation></ref><ref id="bib0049"><element-citation publication-type="journal" id="sbref0049"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.Y.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name></person-group><article-title>Recent advances in Kawasaki disease</article-title><source>Yonsei Med. J.</source><volume>57</volume><year>2016</year><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">26632378</pub-id></element-citation></ref><ref id="bib0050"><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>H.-C.</given-names></name><name><surname>Chang</surname><given-names>J.-C.</given-names></name><name><surname>Kuo</surname><given-names>H.-C.</given-names></name><name><surname>Yu</surname><given-names>H.-R.</given-names></name><name><surname>Wang</surname><given-names>C.-L.</given-names></name><name><surname>Lee</surname><given-names>C.-P.</given-names></name><name><surname>Huang</surname><given-names>L.-T.</given-names></name><name><surname>Yang</surname><given-names>K.D.</given-names></name></person-group><article-title>Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array</article-title><source>Arthritis Rheumatol.</source><volume>67</volume><year>2015</year><fpage>828</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">25470559</pub-id></element-citation></ref><ref id="bib0051"><element-citation publication-type="journal" id="sbref0051"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>H.C.</given-names></name><name><surname>Chang</surname><given-names>J.C.</given-names></name><name><surname>Guo</surname><given-names>M.M.H.</given-names></name><name><surname>Hsieh</surname><given-names>K.S.</given-names></name><name><surname>Yeter</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>S.C.</given-names></name><name><surname>Yang</surname><given-names>K.D.</given-names></name></person-group><article-title>Gene-gene associations with the susceptibility of Kawasaki disease and coronary artery lesions</article-title><source>PLoS One</source><volume>10</volume><year>2015</year></element-citation></ref><ref id="bib0052"><mixed-citation publication-type="other" id="othref0001">Kuo, H.C., Chao, M.C., Hsu, Y.W., Lin, Y.C., Huang, Y.H., Yu, H.R., Hou, M.F., Liang, C.D., Yang, K.D., Chang, W.C., Wang, C.L., 2012. CD40 gene polymorphisms associated with susceptibility and coronary artery lesions of Kawasaki disease in the Taiwanese population. Sci. World J.</mixed-citation></ref><ref id="bib0053"><element-citation publication-type="journal" id="sbref0052"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>H.C.</given-names></name><name><surname>Yang</surname><given-names>K.D.</given-names></name><name><surname>Liang</surname><given-names>C.D.</given-names></name><name><surname>Bong</surname><given-names>C.N.</given-names></name><name><surname>Yu</surname><given-names>H.R.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>C.L.</given-names></name></person-group><article-title>The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease</article-title><source>Pediatr. Allergy Immunol.</source><volume>18</volume><year>2007</year><fpage>354</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">17584314</pub-id></element-citation></ref><ref id="bib0054"><element-citation publication-type="journal" id="sbref0053"><person-group person-group-type="author"><name><surname>Kuwabara</surname><given-names>M.</given-names></name><name><surname>Yashiro</surname><given-names>M.</given-names></name><name><surname>Kotani</surname><given-names>K.</given-names></name><name><surname>Tsuboi</surname><given-names>S.</given-names></name><name><surname>Ae</surname><given-names>R.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Yanagawa</surname><given-names>H.</given-names></name><name><surname>Kawasaki</surname><given-names>T.</given-names></name></person-group><article-title>Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan</article-title><source>J. Epidemiol.</source><volume>25</volume><year>2015</year><fpage>189</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">25716055</pub-id></element-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0054"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>Y.-C.</given-names></name><name><surname>Kim</surname><given-names>J.-J.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Yoon</surname><given-names>K.L.</given-names></name><name><surname>Lee</surname><given-names>K.-Y.</given-names></name><name><surname>Kil</surname><given-names>H.-R.</given-names></name><name><surname>Kim</surname><given-names>G.B.</given-names></name><name><surname>Han</surname><given-names>M.-K.</given-names></name><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>H.D.</given-names></name><name><surname>Ha</surname><given-names>K.-S.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Ebata</surname><given-names>R.</given-names></name><name><surname>Hamada</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Onouchi</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Lee</surname><given-names>J.-K.</given-names></name><name><surname>the Korean Kawasaki Disease Genetics</surname><given-names>C.</given-names></name></person-group><article-title>Male-specific association of the FCGR2A His167Arg polymorphism with Kawasaki disease</article-title><source>PLoS One</source><volume>12</volume><year>2017</year><object-id pub-id-type="publisher-id">e0184248</object-id></element-citation></ref><ref id="bib0056"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>X.N.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>Y.F.</given-names></name><name><surname>Cheng</surname><given-names>T.</given-names></name><name><surname>Wan</surname><given-names>J.R.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Pinocembrin protects hemorrhagic brain primarily by inhibiting toll-like receptor 4 and reducing M1 phenotype microglia</article-title><source>Brain Behav. Immun.</source><volume>61</volume><year>2017</year><fpage>326</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">28007523</pub-id></element-citation></ref><ref id="bib0057"><element-citation publication-type="journal" id="sbref0056"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J.K.</given-names></name><name><surname>Hong</surname><given-names>Y.M.</given-names></name><name><surname>Jang</surname><given-names>G.Y.</given-names></name><name><surname>Yun</surname><given-names>S.W.</given-names></name><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Yoon</surname><given-names>K.L.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Kil</surname><given-names>H.R.</given-names></name></person-group><article-title>Consortium-based genetic studies of Kawasaki disease in Korea: Korean Kawasaki disease genetics consortium</article-title><source>Korean Circ. J.</source><volume>45</volume><year>2015</year><fpage>443</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">26617644</pub-id></element-citation></ref><ref id="bib0058"><element-citation publication-type="journal" id="sbref0057"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.-Y.</given-names></name><name><surname>Han</surname><given-names>J.-W.</given-names></name><name><surname>Lee</surname><given-names>J.-S.</given-names></name></person-group><article-title>Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora</article-title><source>Med. Hypotheses</source><year>2007</year></element-citation></ref><ref id="bib0059"><element-citation publication-type="journal" id="sbref0058"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.-Y.</given-names></name><name><surname>Rhim</surname><given-names>J.-W.</given-names></name><name><surname>Kang</surname><given-names>J.-H.</given-names></name></person-group><article-title>Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a &#x0201c;protein homeostasis system&#x0201d;</article-title><source>Yonsei Med. J.</source><volume>53</volume><year>2012</year><fpage>262</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">22318812</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="journal" id="sbref0059"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.J.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>M.J.</given-names></name><name><surname>Yoon</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>E.J.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name></person-group><article-title>Usefulness of anterior uveitis as an additional tool for diagnosing incomplete Kawasaki disease</article-title><source>Korean J. Pediatr.</source><volume>59</volume><year>2016</year><fpage>174</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">27186227</pub-id></element-citation></ref><ref id="bib0061"><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.B.</given-names></name><name><surname>Kim</surname><given-names>Y.H.</given-names></name><name><surname>Hyun</surname><given-names>M.C.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>Y.H.</given-names></name></person-group><article-title>T-Helper cytokine profiles in patients with Kawasaki disease</article-title><source>Korean Circ. J.</source><volume>45</volume><year>2015</year><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">26617655</pub-id></element-citation></ref><ref id="bib0062"><element-citation publication-type="journal" id="sbref0061"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.J.</given-names></name><name><surname>Vim</surname><given-names>K.H.</given-names></name><name><surname>Chun</surname><given-names>J.K.</given-names></name><name><surname>Kim</surname><given-names>D.S.</given-names></name></person-group><article-title>Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease</article-title><source>Yonsei Med. J.</source><volume>49</volume><year>2008</year><fpage>714</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">18972590</pub-id></element-citation></ref><ref id="bib0063"><element-citation publication-type="journal" id="sbref0062"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.C.</given-names></name><name><surname>Kuo</surname><given-names>H.C.</given-names></name><name><surname>Chang</surname><given-names>J.S.</given-names></name><name><surname>Chang</surname><given-names>L.Y.</given-names></name><name><surname>Huang</surname><given-names>L.M.</given-names></name><name><surname>Chen</surname><given-names>M.R.</given-names></name><name><surname>Liang</surname><given-names>C.D.</given-names></name><name><surname>Chi</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>F.Y.</given-names></name><name><surname>Lee</surname><given-names>M.L.</given-names></name><name><surname>Huang</surname><given-names>Y.C.</given-names></name><name><surname>Hwang</surname><given-names>B.</given-names></name><name><surname>Chiu</surname><given-names>N.C.</given-names></name><name><surname>Hwang</surname><given-names>K.P.</given-names></name><name><surname>Lee</surname><given-names>P.C.</given-names></name><name><surname>Chang</surname><given-names>L.C.</given-names></name><name><surname>Liu</surname><given-names>Y.M.</given-names></name><name><surname>Chen</surname><given-names>Y.J.</given-names></name><name><surname>Chen</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>Y.T.</given-names></name><name><surname>Tsai</surname><given-names>F.J.</given-names></name><name><surname>Wu</surname><given-names>J.Y.</given-names></name><name><surname>Taiwan Pediat</surname><given-names>I.D.A.</given-names></name></person-group><article-title>Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis</article-title><source>Nat. Genet.</source><volume>44</volume><year>2012</year><comment>522-+</comment></element-citation></ref><ref id="bib0064"><element-citation publication-type="journal" id="sbref0063"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>B.</given-names></name><name><surname>Tang</surname><given-names>F.T.</given-names></name><name><surname>Lu</surname><given-names>M.L.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.X.</given-names></name><name><surname>Zhang</surname><given-names>Y.J.</given-names></name></person-group><article-title>Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-kappa B signaling pathway</article-title><source>Life Sci.</source><volume>209</volume><year>2018</year><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">30081006</pub-id></element-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0064"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Lu</surname><given-names>L.H.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Tu</surname><given-names>P.F.</given-names></name></person-group><article-title>Qishen granules inhibit myocardial inflammation injury through regulating arachidonic acid metabolism</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year></element-citation></ref><ref id="bib0066"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z.J.</given-names></name><name><surname>Meng</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>R.J.</given-names></name><name><surname>Huang</surname><given-names>G.Y.</given-names></name><name><surname>Ma</surname><given-names>X.J.</given-names></name><name><surname>Chen</surname><given-names>J.J.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>M.R.</given-names></name><name><surname>Gui</surname><given-names>Y.H.</given-names></name><name><surname>Chu</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Kan</surname><given-names>H.D.</given-names></name></person-group><article-title>Ambient air pollution, temperature and Kawasaki disease in Shanghai, China</article-title><source>Chemosphere</source><volume>186</volume><year>2017</year><fpage>817</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">28822259</pub-id></element-citation></ref><ref id="bib0067"><element-citation publication-type="journal" id="sbref0066"><person-group person-group-type="author"><name><surname>Linlin</surname><given-names>R.</given-names></name><name><surname>Caixia</surname><given-names>W.</given-names></name><name><surname>Jing</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Therapeutic effect of traditional Chinese medicine combined with gamma globulin and aspirin on Kawasaki disease</article-title><source>Modern J. Integr. Tradit. Chin. West. Med.</source><volume>25</volume><year>2016</year><fpage>1890</fpage><lpage>1892</lpage></element-citation></ref><ref id="bib0068"><element-citation publication-type="journal" id="sbref0067"><person-group person-group-type="author"><name><surname>Linlin</surname><given-names>R.</given-names></name><name><surname>Jing</surname><given-names>L.</given-names></name><name><surname>Caixia</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Clinical observation on 50 cases of Kawasaki disease treated by integrative Chinese and western medicine</article-title><source>J. Sichuan Tradit. Chin. Med.</source><volume>34</volume><year>2016</year><fpage>138</fpage><lpage>139</lpage></element-citation></ref><ref id="bib0069"><element-citation publication-type="journal" id="sbref0068"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Clinical observation on treatment of Kawasaki disease with Jiedu Huayu decoction combined with gamma globulin</article-title><source>Shaanxi J. Tradit. Chin. Med.</source><volume>180</volume><year>2017</year></element-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0069"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name></person-group><article-title>Suppressive effect of glycyrrhizic acid against lipopolysaccharide-induced neuroinflammation and cognitive impairment in C57 mice via toll-like receptor 4 signaling pathway</article-title><source>Food Nutr. Res.</source><volume>63</volume><year>2019</year></element-citation></ref><ref id="bib0071"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Lue</surname><given-names>H.C.</given-names></name><name><surname>Chen</surname><given-names>L.R.</given-names></name><name><surname>Lin</surname><given-names>M.T.</given-names></name><name><surname>Chang</surname><given-names>L.Y.</given-names></name><name><surname>Wang</surname><given-names>J.K.</given-names></name><name><surname>Lee</surname><given-names>C.Y.</given-names></name><name><surname>Wu</surname><given-names>M.H.</given-names></name></person-group><article-title>Epidemiological features of Kawasaki disease in Taiwan, 1976&#x02013;2007: results of five nationwide questionnaire hospital surveys</article-title><source>Pediatr. Neonatol.</source><volume>55</volume><year>2014</year><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">24120536</pub-id></element-citation></ref><ref id="bib0072"><element-citation publication-type="journal" id="sbref0071"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>A.</given-names></name></person-group><article-title>Clinical observation of ligustrazine in the treatment of Kawasaki disease</article-title><source>Chin. Natl. Folk Med.</source><volume>19</volume><year>2010</year><fpage>9</fpage><lpage>10</lpage></element-citation></ref><ref id="bib0073"><element-citation publication-type="journal" id="sbref0072"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Y.W.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.M.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>Y.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Dou</surname><given-names>J.J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>Y.F.</given-names></name><name><surname>Wu</surname><given-names>W.T.</given-names></name><name><surname>Cui</surname><given-names>W.R.</given-names></name><name><surname>Lv</surname><given-names>H.T.</given-names></name></person-group><article-title>Understanding the pathogenesis of Kawasaki disease by network and pathway analysis</article-title><source>Comput. Math. Methods Med.</source><year>2013</year></element-citation></ref><ref id="bib0074"><mixed-citation publication-type="other" id="othref0002">Maconochie, I.K., 2004. Kawasaki disease. Archives of disease in childhood - Education &#x00026; practice edition 89, ep3-ep8.</mixed-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0073"><person-group person-group-type="author"><name><surname>Majdi</surname><given-names>F</given-names></name><name><surname>T.F.</surname><given-names>Salehi P</given-names></name><name><surname>Motaghinejad</surname><given-names>M</given-names></name><name><surname>Safari</surname><given-names>S</given-names></name></person-group><article-title>Cannabinoids &#x00394;9-tetrahydrocannabinol and cannabidiol may be effective against methamphetamine induced mitochondrial dysfunction and inflammation by modulation of Toll-like type-4(Toll-like 4) receptors and NF-&#x003ba;B signaling</article-title><source>Med. Hypotheses</source><volume>133</volume><year>2019</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="bib0076"><element-citation publication-type="journal" id="sbref0074"><person-group person-group-type="author"><name><surname>McCrindle</surname><given-names>B.W.</given-names></name><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Bolger</surname><given-names>A.F.</given-names></name><name><surname>Gewitz</surname><given-names>M.</given-names></name><name><surname>Baker</surname><given-names>A.L.</given-names></name><name><surname>Jackson</surname><given-names>M.A.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>P.B.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>M.H.</given-names></name><name><surname>Saji</surname><given-names>T.T.</given-names></name><name><surname>Pahl</surname><given-names>E.</given-names></name><name><surname>Amer Heart</surname><given-names>A.</given-names></name><name><surname>Council Cardiovascular Stroke</surname><given-names>N.</given-names></name><name><surname>Council Cardiovascular Surg</surname><given-names>A.</given-names></name><name><surname>Council Epidemiology</surname><given-names>P.</given-names></name></person-group><article-title>Diagnosis, treatment, and long-term management of Kawasaki disease a scientific statement for health professionals from the American Heart Association</article-title><source>Circulation</source><volume>135</volume><year>2017</year><fpage>E927</fpage><lpage>E999</lpage><pub-id pub-id-type="pmid">28356445</pub-id></element-citation></ref><ref id="bib0077"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Medeiros</surname><given-names>K.C.P.</given-names></name><name><surname>Faustino</surname><given-names>L.</given-names></name><name><surname>Borduchi</surname><given-names>E.</given-names></name><name><surname>Nascimento</surname><given-names>R.J.B.</given-names></name><name><surname>Silva</surname><given-names>T.M.S.</given-names></name><name><surname>Gomes</surname><given-names>E.</given-names></name><name><surname>Piuvezam</surname><given-names>M.R.</given-names></name><name><surname>Russo</surname><given-names>M.</given-names></name></person-group><article-title>Preventive and curative glycoside kaempferol treatments attenuate the TH2-driven allergic airway disease</article-title><source>Int. Immunopharmacol.</source><volume>9</volume><year>2009</year><fpage>1540</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">19755174</pub-id></element-citation></ref><ref id="bib0078"><element-citation publication-type="journal" id="sbref0076"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>K.</given-names></name><name><surname>Kaneko</surname><given-names>T.</given-names></name><name><surname>Morikawa</surname><given-names>Y.</given-names></name><name><surname>Sakakibara</surname><given-names>H.</given-names></name><name><surname>Matsushima</surname><given-names>T.</given-names></name><name><surname>Misawa</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Nakazawa</surname><given-names>M.</given-names></name><name><surname>Tamame</surname><given-names>T.</given-names></name><name><surname>Tsuchihashi</surname><given-names>T.</given-names></name><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Obonai</surname><given-names>T.</given-names></name><name><surname>Chiga</surname><given-names>M.</given-names></name><name><surname>Hori</surname><given-names>N.</given-names></name><name><surname>Komiyama</surname><given-names>O.</given-names></name><name><surname>Yamagishi</surname><given-names>H.</given-names></name><name><surname>Miura</surname><given-names>M.</given-names></name></person-group><article-title>Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study</article-title><source>Lancet Child Adolesc. Health</source><volume>2</volume><year>2018</year><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">30337183</pub-id></element-citation></ref><ref id="bib0079"><element-citation publication-type="journal" id="sbref0077"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>K.P.</given-names></name><name><surname>Kim</surname><given-names>B.J.</given-names></name><name><surname>Lee</surname><given-names>K.J.</given-names></name><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name></person-group><article-title>Prediction of nonresponsiveness to medium-dose intravenous immunoglobulin (1&#x000a0;g/kg) treatment: an effective and safe schedule of acute treatment for Kawasaki disease</article-title><source>Korean J. Pediatr.</source><volume>59</volume><year>2016</year><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">27186228</pub-id></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0078"><person-group person-group-type="author"><name><surname>Nejihashi</surname><given-names>Y.</given-names></name><name><surname>Takada</surname><given-names>Y.</given-names></name><name><surname>Okazaki</surname><given-names>T.</given-names></name></person-group><article-title>An autopsied case of Reye syndrome in progress of MCLS</article-title><source>Shonika Shinryo</source><volume>43</volume><year>1980</year><fpage>960</fpage><lpage>962</lpage></element-citation></ref><ref id="bib0081"><element-citation publication-type="journal" id="sbref0079"><person-group person-group-type="author"><name><surname>Neng</surname><given-names>H.</given-names></name><name><surname>Youxian</surname><given-names>D.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name></person-group><article-title>Treatment of 18 Cases of Kawasaki Disease with Coronary Aneurysm with Ligustrazine</article-title><source>Hubei J. Tradit. Chin. Med.</source><volume>18</volume><year>1996</year><fpage>9</fpage><lpage>10</lpage></element-citation></ref><ref id="bib0082"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Takahashi</surname><given-names>M.</given-names></name><name><surname>Gerber</surname><given-names>M.A.</given-names></name><name><surname>Gewitz</surname><given-names>M.H.</given-names></name><name><surname>Tani</surname><given-names>L.Y.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Bolger</surname><given-names>A.F.</given-names></name><name><surname>Ferrieri</surname><given-names>P.</given-names></name><name><surname>Baltimore</surname><given-names>R.S.</given-names></name><name><surname>Wilson</surname><given-names>W.R.</given-names></name><name><surname>Baddour</surname><given-names>L.M.</given-names></name><name><surname>Levison</surname><given-names>M.E.</given-names></name><name><surname>Pallasch</surname><given-names>T.J.</given-names></name><name><surname>Falace</surname><given-names>D.A.</given-names></name><name><surname>Taubert</surname><given-names>K.A.</given-names></name></person-group><article-title>Diagnosis, treatment, and long-term management of Kawasaki disease &#x02013; a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young</article-title><source>Am. Heart Assoc. Circul.</source><volume>110</volume><year>2004</year><fpage>2747</fpage><lpage>2771</lpage></element-citation></ref><ref id="bib0083"><element-citation publication-type="journal" id="sbref0081"><person-group person-group-type="author"><name><surname>Ogihara</surname><given-names>Y.</given-names></name><name><surname>Ogata</surname><given-names>S.</given-names></name><name><surname>Nomoto</surname><given-names>K.</given-names></name><name><surname>Ebato</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>K.</given-names></name><name><surname>Kokubo</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Ishii</surname><given-names>M.</given-names></name></person-group><article-title>Transcriptional regulation by infliximab therapy in kawasaki disease patients with immunoglobulin resistance</article-title><source>Pediatr. Res.</source><volume>76</volume><year>2014</year><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">24964229</pub-id></element-citation></ref><ref id="bib0084"><element-citation publication-type="journal" id="sbref0082"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name><name><surname>Suh</surname><given-names>B.K.</given-names></name><name><surname>Koh</surname><given-names>D.K.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Oh</surname><given-names>C.K.</given-names></name><name><surname>Kim</surname><given-names>T.G.</given-names></name><name><surname>Choi</surname><given-names>H.B.</given-names></name></person-group><article-title>Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease</article-title><source>Pediatr. Cardiol.</source><volume>29</volume><year>2008</year><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">18064508</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal" id="optkE0V93qzdR"><person-group person-group-type="author"><name><surname>O&#x02019;Loughlin</surname><given-names>J.E.</given-names></name></person-group><article-title>Management of Kawasaki Syndrome: A Consensus Statement Prepared by North American Participants of the Third International Kawasaki Disease Symposium, Tokyo, Japan</article-title><source>PIDJ.</source><volume>8</volume><year>1989</year><fpage>663</fpage><lpage>667</lpage></element-citation></ref><ref id="bib0085"><element-citation publication-type="journal" id="sbref0083"><person-group person-group-type="author"><name><surname>Onouchi</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular genetics of Kawasaki disease</article-title><source>Pediatr. Res.</source><volume>65</volume><year>2009</year><fpage>46R</fpage><lpage>54R</lpage></element-citation></ref><ref id="bib0086"><element-citation publication-type="journal" id="sbref0084"><person-group person-group-type="author"><name><surname>Onouchi</surname><given-names>Y.</given-names></name></person-group><article-title>Identification of susceptibility genes for Kawasaki disease</article-title><source>Nihon Rinsho Meneki Gakkai Kaishi</source><volume>33</volume><year>2010</year><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">20453442</pub-id></element-citation></ref><ref id="bib0087"><mixed-citation publication-type="other" id="othref0003">Onouchi, Y., 2012. Genetics of Kawasaki disease &#x02013; what we know and don't know, Japan, p. 1581.</mixed-citation></ref><ref id="bib0088"><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Onouchi</surname><given-names>Y.</given-names></name></person-group><article-title>Identification of susceptibility genes for Kawasaki disease</article-title><source>Chiba Med. J.</source><volume>91</volume><year>2015</year><fpage>1</fpage><lpage>16</lpage></element-citation></ref><ref id="bib0089"><element-citation publication-type="journal" id="sbref0086"><person-group person-group-type="author"><name><surname>Onouchi</surname><given-names>Y.</given-names></name><name><surname>Ozaki</surname><given-names>K.</given-names></name><name><surname>Buns</surname><given-names>J.C.</given-names></name><name><surname>Shimizu</surname><given-names>C.</given-names></name><name><surname>Hamada</surname><given-names>H.</given-names></name><name><surname>Honda</surname><given-names>T.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Honda</surname><given-names>A.</given-names></name><name><surname>Takeuchi</surname><given-names>T.</given-names></name><name><surname>Shibuta</surname><given-names>S.</given-names></name><name><surname>Suenaga</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Higashi</surname><given-names>K.</given-names></name><name><surname>Yasukawa</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Sasago</surname><given-names>K.</given-names></name><name><surname>Kemmotsu</surname><given-names>Y.</given-names></name><name><surname>Takatsuki</surname><given-names>S.</given-names></name><name><surname>Saji</surname><given-names>T.</given-names></name><name><surname>Yoshikawa</surname><given-names>T.</given-names></name><name><surname>Nagai</surname><given-names>T.</given-names></name><name><surname>Hamamoto</surname><given-names>K.</given-names></name><name><surname>Kishi</surname><given-names>F.</given-names></name><name><surname>Ouchi</surname><given-names>K.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Baker</surname><given-names>A.L.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Yashiro</surname><given-names>M.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Wakui</surname><given-names>K.</given-names></name><name><surname>Fukushima</surname><given-names>Y.</given-names></name><name><surname>Fujino</surname><given-names>A.</given-names></name><name><surname>Tsunoda</surname><given-names>T.</given-names></name><name><surname>Kawasaki</surname><given-names>T.</given-names></name><name><surname>Hata</surname><given-names>A.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name></person-group><article-title>Common variants in CASP3 confer susceptibility to Kawasaki disease</article-title><source>Hum. Mol. Genet.</source><volume>19</volume><year>2010</year><fpage>2898</fpage><lpage>2906</lpage><pub-id pub-id-type="pmid">20423928</pub-id></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0087"><person-group person-group-type="author"><name><surname>Onouchi</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Yasukawa</surname><given-names>K.</given-names></name><name><surname>Hamada</surname><given-names>H.</given-names></name><name><surname>Suenaga</surname><given-names>T.</given-names></name><name><surname>Honda</surname><given-names>T.</given-names></name><name><surname>Honda</surname><given-names>A.</given-names></name><name><surname>Kobayashi</surname><given-names>H.</given-names></name><name><surname>Takeuchi</surname><given-names>T.</given-names></name><name><surname>Yoshikawa</surname><given-names>N.</given-names></name><name><surname>Sato</surname><given-names>J.</given-names></name><name><surname>Shibuta</surname><given-names>S.</given-names></name><name><surname>Miyawaki</surname><given-names>M.</given-names></name><name><surname>Oishi</surname><given-names>K.</given-names></name><name><surname>Yamaga</surname><given-names>H.</given-names></name><name><surname>Aoyagi</surname><given-names>N.</given-names></name><name><surname>Iwahashi</surname><given-names>S.</given-names></name><name><surname>Miyashita</surname><given-names>R.</given-names></name><name><surname>Murata</surname><given-names>Y.</given-names></name><name><surname>Ebata</surname><given-names>R.</given-names></name><name><surname>Higashi</surname><given-names>K.</given-names></name><name><surname>Ozaki</surname><given-names>K.</given-names></name><name><surname>Sasago</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Hata</surname><given-names>A.</given-names></name></person-group><article-title>ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease</article-title><source>Pharmacogenom. J.</source><volume>13</volume><year>2011</year><fpage>52</fpage></element-citation></ref><ref id="bib0091"><element-citation publication-type="journal" id="sbref0088"><person-group person-group-type="author"><name><surname>Ou-Yang</surname><given-names>M.C.</given-names></name><name><surname>Kuo</surname><given-names>H.C.</given-names></name><name><surname>Lin</surname><given-names>I.C.</given-names></name><name><surname>Sheen</surname><given-names>J.M.</given-names></name><name><surname>Huang</surname><given-names>F.C.</given-names></name><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Huang</surname><given-names>Y.H.</given-names></name><name><surname>Lin</surname><given-names>Y.J.</given-names></name><name><surname>Yu</surname><given-names>H.R.</given-names></name></person-group><article-title>Plasma clusterin concentrations may predict resistance to intravenous immunoglobulin in patients with Kawasaki disease</article-title><source>Sci. World J.</source><volume>5</volume><year>2013</year></element-citation></ref><ref id="bib0092"><element-citation publication-type="book" id="sbref0089"><person-group person-group-type="author"><name><surname>Pilania</surname><given-names>R.K.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name></person-group><chapter-title>Kawasaki Disease</chapter-title><person-group person-group-type="editor"><name><surname>Cimaz</surname><given-names>R.</given-names></name></person-group><source>Periodic and Non-Periodic Fevers</source><year>2020</year><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc><fpage>45</fpage><lpage>63</lpage></element-citation></ref><ref id="bib0093"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Portman</surname><given-names>M.A.</given-names></name></person-group><article-title>Kawasaki disease and soy: potential role for isoflavone interaction with Fc gamma receptors</article-title><source>Pediatr. Res.</source><volume>73</volume><year>2013</year><fpage>130</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">23168576</pub-id></element-citation></ref><ref id="bib0094"><element-citation publication-type="journal" id="sbref0091"><person-group person-group-type="author"><name><surname>Portman</surname><given-names>M.A.</given-names></name><name><surname>Navarro</surname><given-names>S.L.</given-names></name><name><surname>Bruce</surname><given-names>M.E.</given-names></name><name><surname>Lampe</surname><given-names>J.W.</given-names></name></person-group><article-title>Soy isoflavone intake is associated with risk of Kawasaki disease</article-title><source>Nutr. Res.</source><volume>36</volume><year>2016</year><fpage>827</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">27440537</pub-id></element-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0092"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>P.</given-names></name><name><surname>Chang-hui</surname><given-names>C.</given-names></name><name><surname>Qing</surname><given-names>W.U.</given-names></name><name><surname>Yuan</surname><given-names>Y.</given-names></name></person-group><article-title>Meta-analyses of the associations of genome-wide association study-linked gene loci with Kawasaki disease</article-title><source>Chin. J. Pediatr.</source><volume>571</volume><year>2013</year></element-citation></ref><ref id="bib0096"><element-citation publication-type="journal" id="sbref0093"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Z.</given-names></name><name><surname>Dian</surname><given-names>L.I.U.</given-names></name><name><surname>Min</surname><given-names>S.U.</given-names></name></person-group><article-title>Clinical effect of integrated traditional Chinese and western medicine treatment on Kawasaki disease</article-title><source>Clin. Res. Pract.</source><year>2017</year><fpage>123</fpage></element-citation></ref><ref id="bib0097"><element-citation publication-type="journal" id="sbref0094"><person-group person-group-type="author"><name><surname>Razavi</surname><given-names>B.M.</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H.</given-names></name><name><surname>Abnous</surname><given-names>K.</given-names></name><name><surname>Khoei</surname><given-names>A.</given-names></name><name><surname>Imenshahidi</surname><given-names>M.</given-names></name></person-group><article-title>Protective effect of crocin against apoptosis induced by subchronic exposure of the rat vascular system to diazinon</article-title><source>Toxicol. Ind. Health</source><volume>32</volume><year>2016</year><fpage>1237</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">27353299</pub-id></element-citation></ref><ref id="bib0098"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Remington</surname><given-names>P.L.</given-names></name><name><surname>Shabino</surname><given-names>C.L.</given-names></name><name><surname>McGee</surname><given-names>H.</given-names></name><name><surname>Preston</surname><given-names>G.</given-names></name><name><surname>Sarniak</surname><given-names>A.P.</given-names></name><name><surname>Hall</surname><given-names>W.N.</given-names></name></person-group><article-title>Reye syndrome and juvenile rheumatoid-arthritis in Michigan</article-title><source>Am. J. Dis. Child.</source><volume>139</volume><year>1985</year><fpage>870</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">4036917</pub-id></element-citation></ref><ref id="bib0099"><element-citation publication-type="journal" id="sbref0096"><person-group person-group-type="author"><name><surname>Rezai-Zadeh</surname><given-names>K.</given-names></name><name><surname>Ehrhart</surname><given-names>J.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Sanberg</surname><given-names>P.R.</given-names></name><name><surname>Bickford</surname><given-names>P.</given-names></name><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Shytle</surname><given-names>R.D.</given-names></name></person-group><article-title>Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression</article-title><source>J. Neuroinflamm.</source><volume>5</volume><year>2008</year></element-citation></ref><ref id="bib0100"><element-citation publication-type="journal" id="sbref0097"><person-group person-group-type="author"><name><surname>Rhim</surname><given-names>J.-W.</given-names></name><name><surname>Kang</surname><given-names>H.M.</given-names></name><name><surname>Han</surname><given-names>J.-W.</given-names></name><name><surname>Lee</surname><given-names>K.-Y.</given-names></name></person-group><article-title>A presumed etiology of Kawasaki disease based on epidemiological comparison with infectious or immune-mediated diseases</article-title><source>Front. Pediatr.</source><volume>7</volume><year>2019</year></element-citation></ref><ref id="bib0101"><element-citation publication-type="journal" id="sbref0098"><person-group person-group-type="author"><name><surname>Rhim</surname><given-names>J.W.</given-names></name><name><surname>Youn</surname><given-names>Y.S.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>S.J.</given-names></name><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name></person-group><article-title>Changes in Kawasaki disease during 2 decades at a single institution in Daejeon, Korea</article-title><source>Pediatr. Infect. Dis. J.</source><volume>33</volume><year>2014</year><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">24145172</pub-id></element-citation></ref><ref id="bib0102"><element-citation publication-type="journal" id="sbref0099"><person-group person-group-type="author"><name><surname>Rodo</surname><given-names>X.</given-names></name><name><surname>Curcoll</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>M.</given-names></name><name><surname>Ballester</surname><given-names>J.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Cayan</surname><given-names>D.R.</given-names></name><name><surname>Lipkin</surname><given-names>W.I.</given-names></name><name><surname>Williams</surname><given-names>B.L.</given-names></name><name><surname>Couto-Rodriguez</surname><given-names>M.</given-names></name><name><surname>Nakamura</surname><given-names>Y.</given-names></name><name><surname>Uehara</surname><given-names>R.</given-names></name><name><surname>Tanimoto</surname><given-names>H.</given-names></name><name><surname>Morgui</surname><given-names>J.A.</given-names></name></person-group><article-title>Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan</article-title><source>Proc. Natl. Acad. Sci. US A</source><volume>111</volume><year>2014</year><fpage>7952</fpage><lpage>7957</lpage></element-citation></ref><ref id="bib0103"><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Kim</surname><given-names>K.Y.A.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Yang</surname><given-names>A.</given-names></name><name><surname>Arrollo</surname><given-names>D.</given-names></name><name><surname>DeBerge</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>S.L.</given-names></name><name><surname>Sibinga</surname><given-names>N.E.S.</given-names></name><name><surname>Pink</surname><given-names>A.J.</given-names></name><name><surname>Thorp</surname><given-names>E.B.</given-names></name></person-group><article-title>Allograft inflammatory factor-1 links T-Cell activation, interferon response, and macrophage activation in chronic Kawasaki disease arteritis</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><volume>6</volume><year>2017</year><fpage>E94</fpage><lpage>E102</lpage></element-citation></ref><ref id="bib0104"><element-citation publication-type="journal" id="sbref0101"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name><name><surname>Orenstein</surname><given-names>J.M.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name></person-group><article-title>Opinion &#x02013; searching for the cause of Kawasaki disease &#x02013; cytoplasmic inclusion bodies provide new insight</article-title><source>Nat. Rev. Microbiol.</source><volume>6</volume><year>2008</year><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">18364728</pub-id></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0102"><person-group person-group-type="author"><name><surname>Rowley</surname><given-names>A.H.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name></person-group><article-title>Kawasaki syndrome</article-title><source>Clin. Microbiol. Rev.</source><volume>11</volume><year>1998</year><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">9665974</pub-id></element-citation></ref><ref id="bib0106"><element-citation publication-type="journal" id="sbref0103"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>X.D.</given-names></name></person-group><article-title>Clinical Characteristics of Kawasaki syndrome and the risk factors for coronary artery lesions in China</article-title><source>Pediatr. Infect. Dis. J.</source><volume>32</volume><year>2013</year><fpage>E397</fpage><lpage>E402</lpage><pub-id pub-id-type="pmid">23722531</pub-id></element-citation></ref><ref id="bib0107"><element-citation publication-type="journal" id="sbref0104"><person-group person-group-type="author"><name><surname>Ruo-Sha</surname><given-names>L.</given-names></name><name><surname>Shu-Juan</surname><given-names>D.</given-names></name></person-group><article-title>Effect of heat-clearing and blood-activating herbs on platelet parameters in children with Kawasaki disease</article-title><source>J. Guangzhou Univ. Tradit. Chin. Med.</source><volume>492</volume><year>2008</year></element-citation></ref><ref id="bib0108"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Saguil</surname><given-names>A.</given-names></name><name><surname>Fargo</surname><given-names>M.</given-names></name><name><surname>Grogan</surname><given-names>S.</given-names></name></person-group><article-title>Diagnosis and management of kawasaki disease</article-title><source>Am. Fam. Phys.</source><volume>91</volume><year>2015</year><fpage>365</fpage><lpage>371</lpage></element-citation></ref><ref id="bib0109"><element-citation publication-type="journal" id="sbref0106"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>S.</given-names></name><name><surname>Kawashima</surname><given-names>H.</given-names></name><name><surname>Kashiwagi</surname><given-names>Y.</given-names></name><name><surname>Hoshika</surname><given-names>A.</given-names></name></person-group><article-title>Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients</article-title><source>Int. J. Rheum. Dis.</source><volume>16</volume><year>2013</year><fpage>168</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">23773640</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0107"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>Y.M.</given-names></name><name><surname>Kang</surname><given-names>H.M.</given-names></name><name><surname>Lee</surname><given-names>S.C.</given-names></name><name><surname>Yu</surname><given-names>J.W.</given-names></name><name><surname>Kil</surname><given-names>H.R.</given-names></name><name><surname>Rhim</surname><given-names>J.W.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Lee</surname><given-names>K.Y.</given-names></name></person-group><article-title>Clinical implications in laboratory parameter values in acute Kawasaki disease for early diagnosis and proper treatment</article-title><source>Korean J. Pediatr.</source><volume>61</volume><year>2018</year><fpage>160</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">29853941</pub-id></element-citation></ref><ref id="bib0111"><element-citation publication-type="journal" id="sbref0108"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Rowley</surname><given-names>A.H.</given-names></name></person-group><article-title>Kawasaki disease: insights into pathogenesis and approaches to treatment</article-title><source>Nat. Rev. Rheumatol.</source><volume>11</volume><year>2015</year><fpage>475</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">25907703</pub-id></element-citation></ref><ref id="bib0112"><element-citation publication-type="journal" id="sbref0109"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>L.T.</given-names></name><name><surname>Nelson</surname><given-names>S.</given-names></name><name><surname>Short</surname><given-names>E.</given-names></name><name><surname>Min</surname><given-names>M.O.</given-names></name><name><surname>Lewis</surname><given-names>B.</given-names></name><name><surname>Russ</surname><given-names>S.</given-names></name><name><surname>Minnes</surname><given-names>S.</given-names></name></person-group><article-title>Prenatal cocaine exposure: drug and environmental effects at 9 years</article-title><source>J. Pediatr.</source><volume>153</volume><year>2008</year><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">18571546</pub-id></element-citation></ref><ref id="bib0113"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Vignesh</surname><given-names>P.</given-names></name><name><surname>Burgner</surname><given-names>D.</given-names></name></person-group><article-title>The epidemiology of Kawasaki disease: a global update</article-title><source>Arch. Disease Child.</source><volume>100</volume><year>2015</year><fpage>1084</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">26111818</pub-id></element-citation></ref><ref id="bib0114"><element-citation publication-type="journal" id="sbref0111"><person-group person-group-type="author"><name><surname>Sleeper</surname><given-names>L.A.</given-names></name><name><surname>Minich</surname><given-names>L.L.</given-names></name><name><surname>McCrindle</surname><given-names>B.M.</given-names></name><name><surname>Li</surname><given-names>J.S.</given-names></name><name><surname>Mason</surname><given-names>W.</given-names></name><name><surname>Colan</surname><given-names>S.D.</given-names></name><name><surname>Atz</surname><given-names>A.M.</given-names></name><name><surname>Printz</surname><given-names>B.F.</given-names></name><name><surname>Baker</surname><given-names>A.</given-names></name><name><surname>Vetter</surname><given-names>V.L.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Pediat Heart Network</surname><given-names>I.</given-names></name></person-group><article-title>Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance</article-title><source>J. Pediatr.</source><volume>158</volume><year>2011</year><fpage>831</fpage><lpage>U169</lpage><pub-id pub-id-type="pmid">21168857</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0112"><person-group person-group-type="author"><name><surname>Son</surname><given-names>M.B.</given-names></name><name><surname>Gauvreau</surname><given-names>K.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Corinaldesi</surname><given-names>E.</given-names></name><name><surname>Tremoulet</surname><given-names>A.H.</given-names></name><name><surname>Watson</surname><given-names>V.E.</given-names></name><name><surname>Baker</surname><given-names>A.</given-names></name><name><surname>Fulton</surname><given-names>D.R.</given-names></name><name><surname>Sundel</surname><given-names>R.P.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name></person-group><article-title>Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study</article-title><source>J. Pediatr.</source><volume>158</volume><year>2011</year><fpage>644</fpage><lpage>U157</lpage><pub-id pub-id-type="pmid">21129756</pub-id></element-citation></ref><ref id="bib0116"><element-citation publication-type="book" id="sbref0113"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M.S.</given-names></name><name><surname>Lee</surname><given-names>S.B.</given-names></name><name><surname>Sohn</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>J.H.</given-names></name><name><surname>Yoon</surname><given-names>K.L.</given-names></name><name><surname>Han</surname><given-names>J.W.</given-names></name><name><surname>Kim</surname><given-names>C.H.</given-names></name></person-group><chapter-title>Infliximab Treatment for Refractory Kawasaki Disease in Korean Children</chapter-title><year>2010</year><publisher-name>The Korean Society of Cardiology</publisher-name><publisher-loc>United States, North America</publisher-loc></element-citation></ref><ref id="bib0117"><element-citation publication-type="journal" id="sbref0114"><person-group person-group-type="author"><name><surname>Stock</surname><given-names>A.T.</given-names></name><name><surname>Jama</surname><given-names>H.A.</given-names></name><name><surname>Hansen</surname><given-names>J.A.</given-names></name><name><surname>Wicks</surname><given-names>I.P.</given-names></name></person-group><article-title>TNF and IL-1 play essential but temporally distinct roles in driving cardiac inflammation in a murine model of Kawasaki disease</article-title><source>J. Immunol.</source><volume>202</volume><year>2019</year><fpage>3151</fpage><lpage>3160</lpage><pub-id pub-id-type="pmid">30996002</pub-id></element-citation></ref><ref id="bib0118"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Su</surname><given-names>E.</given-names></name><name><surname>Hsieh</surname><given-names>J.</given-names></name><name><surname>Hsu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name></person-group><article-title>Case report Reye&#x02019;s syndrome arising from the treatment of Kawasaki disease</article-title><source>HK J. Paediatr.</source><volume>23</volume><year>2018</year><fpage>185</fpage><lpage>187</lpage></element-citation></ref><ref id="bib0119"><element-citation publication-type="journal" id="sbref0116"><person-group person-group-type="author"><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name></person-group><article-title>Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose</article-title><source>J. Pediatr.</source><volume>131</volume><year>1997</year><fpage>888</fpage><lpage>893</lpage><pub-id pub-id-type="pmid">9427895</pub-id></element-citation></ref><ref id="bib0120"><element-citation publication-type="journal" id="sbref0117"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.-b.</given-names></name><name><surname>Li</surname><given-names>C.-r.</given-names></name><name><surname>Zu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>W.-g.</given-names></name></person-group><article-title>Changes and significance for regulatory factors for signal pathways of Toll-like receptors in immunological pathogenesis of Kawasaki disease</article-title><source>Chin. J. Pediatr.</source><volume>46</volume><year>2008</year><fpage>49</fpage><lpage>54</lpage></element-citation></ref><ref id="bib0121"><element-citation publication-type="journal" id="sbref0118"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G.B.</given-names></name><name><surname>Li</surname><given-names>C.R.</given-names></name><name><surname>Zu</surname><given-names>Y.</given-names></name></person-group><article-title>Change of MyD88-independent signal transduction of Toll-like receptor 4 in immunological pathogenesis of Kawasaki disease</article-title><source>Zhonghua Er Ke Za Zhi</source><volume>45</volume><year>2007</year><fpage>818</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">18282411</pub-id></element-citation></ref><ref id="bib0122"><element-citation publication-type="journal" id="sbref0119"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Feng</surname><given-names>T.</given-names></name></person-group><article-title>Pay attention to the treatment of Chinese medicine in the acute phase of Kawasaki disease</article-title><source>Modern J. Integr. Tradit. Chin. West. Med.</source><volume>131</volume><year>2002</year></element-citation></ref><ref id="bib0123"><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Niu</surname><given-names>J.</given-names></name><name><surname>Ou</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Zerumbone protects against carbon tetrachloride (CCl4)-induced acute liver injury in mice via inhibiting oxidative stress and the inflammatory response: Involving the TLR4/NF-&#x003ba;B/COX-2 pathway</article-title><source>Molecules</source><volume>24</volume><year>2019</year><fpage>1964</fpage></element-citation></ref><ref id="bib0124"><element-citation publication-type="journal" id="sbref0121"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Treatment of 32 cases of Kawasaki disease with Baihu decoction</article-title><source>Shaanxi J. Tradit. Chin. Med.</source><volume>1458</volume><year>2011</year></element-citation></ref><ref id="bib0125"><element-citation publication-type="journal" id="sbref0122"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Gong</surname><given-names>F.Q.</given-names></name><name><surname>Fu</surname><given-names>S.L.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>Y.Q.</given-names></name><name><surname>Xie</surname><given-names>C.H.</given-names></name><name><surname>Zhang</surname><given-names>Y.Y.</given-names></name></person-group><article-title>Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease</article-title><source>Arthritis Rheum.</source><volume>65</volume><year>2013</year><fpage>805</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">23440694</pub-id></element-citation></ref><ref id="bib0126"><element-citation publication-type="journal" id="sbref0123"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>C.M.</given-names></name><name><surname>Chen</surname><given-names>H.L.</given-names></name><name><surname>Lee</surname><given-names>P.I.</given-names></name><name><surname>Chen</surname><given-names>C.M.</given-names></name><name><surname>Ma</surname><given-names>C.Y.</given-names></name><name><surname>Hwu</surname><given-names>W.L.</given-names></name></person-group><article-title>Reye&#x02019;s syndrome developing in an infant on treatment of Kawasaki syndrome</article-title><source>J. Paediatr. Child Health</source><volume>41</volume><year>2005</year><fpage>303</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">15953335</pub-id></element-citation></ref><ref id="bib0127"><element-citation publication-type="journal" id="sbref0124"><person-group person-group-type="author"><name><surname>Witoelar</surname><given-names>A.</given-names></name><name><surname>Jansen</surname><given-names>I.E.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Desikan</surname><given-names>R.S.</given-names></name><name><surname>Gibbs</surname><given-names>J.R.</given-names></name><name><surname>Blauwendraat</surname><given-names>C.</given-names></name><name><surname>Thompson</surname><given-names>W.K.</given-names></name><name><surname>Hernandez</surname><given-names>D.G.</given-names></name><name><surname>Djurovic</surname><given-names>S.</given-names></name><name><surname>Schork</surname><given-names>A.J.</given-names></name><name><surname>Bettella</surname><given-names>F.</given-names></name><name><surname>Ellinghaus</surname><given-names>D.</given-names></name><name><surname>Franke</surname><given-names>A.</given-names></name><name><surname>Lie</surname><given-names>B.A.</given-names></name><name><surname>McEvoy</surname><given-names>L.K.</given-names></name><name><surname>Karlsen</surname><given-names>T.H.</given-names></name><name><surname>Lesage</surname><given-names>S.</given-names></name><name><surname>Morris</surname><given-names>H.R.</given-names></name><name><surname>Brice</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>N.W.</given-names></name><name><surname>Heutink</surname><given-names>P.</given-names></name><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Singleton</surname><given-names>A.B.</given-names></name><name><surname>Dale</surname><given-names>A.M.</given-names></name><name><surname>Gasser</surname><given-names>T.</given-names></name><name><surname>Andreassen</surname><given-names>O.A.</given-names></name><name><surname>Sharma</surname><given-names>M.</given-names></name><name><surname>International Parkinson&#x02019;s Disease Genomics Consortium</surname><given-names>N.A.B.E.C.</given-names></name><name><surname>United Kingdom Brain Expression Consortium</surname><given-names>I.</given-names></name></person-group><article-title>Genome-wide pleiotropy between Parkinson disease and autoimmune diseases</article-title><source>JAMA Neurol.</source><volume>74</volume><year>2017</year><fpage>780</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">28586827</pub-id></element-citation></ref><ref id="bib0128"><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.F.</given-names></name><name><surname>Misra</surname><given-names>R.S.</given-names></name><name><surname>Russell</surname><given-names>J.Q.</given-names></name><name><surname>Flavell</surname><given-names>R.A.</given-names></name><name><surname>Rincon</surname><given-names>M.</given-names></name><name><surname>Budd</surname><given-names>R.C.</given-names></name></person-group><article-title>Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3</article-title><source>J. Biol. Chem.</source><volume>281</volume><year>2006</year><fpage>10682</fpage><lpage>10690</lpage><pub-id pub-id-type="pmid">16455648</pub-id></element-citation></ref><ref id="bib0129"><element-citation publication-type="journal" id="sbref0126"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.X.</given-names></name><name><surname>Tu</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>G.S.</given-names></name><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Wan</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>M.Y.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.M.</given-names></name><name><surname>Fu</surname><given-names>J.R.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>D.X.</given-names></name></person-group><article-title>Emodin-mediated protection from acute myocardial infarction via inhibition of inflammation and apoptosis in local ischemic myocardium</article-title><source>Life Sci.</source><volume>81</volume><year>2007</year><fpage>1332</fpage><lpage>1338</lpage><pub-id pub-id-type="pmid">17939930</pub-id></element-citation></ref><ref id="bib0130"><element-citation publication-type="journal" id="sbref0127"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>K.P.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Xing</surname><given-names>Z.H.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>S.P.</given-names></name><name><surname>Duan</surname><given-names>M.</given-names></name><name><surname>Sun</surname><given-names>X.H.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Peng</surname><given-names>W.J.</given-names></name></person-group><article-title>Dan-Shen-Yin protects the heart against inflammation and oxidative stress induced by acute ischemic myocardial injury in rats</article-title><source>Exp. Ther. Med.</source><volume>3</volume><year>2012</year><fpage>314</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">22969888</pub-id></element-citation></ref><ref id="bib0131"><element-citation publication-type="journal" id="sbref0128"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y.L.</given-names></name><name><surname>Ma</surname><given-names>Y.Y.</given-names></name><name><surname>Liu</surname><given-names>Y.Q.</given-names></name><name><surname>Hu</surname><given-names>H.D.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.Z.</given-names></name><name><surname>Ma</surname><given-names>Y.X.</given-names></name><name><surname>Tao</surname><given-names>D.C.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Peng</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Combined analysis of genome-wide-linked susceptibility loci to Kawasaki disease in Han Chinese</article-title><source>Hum. Genet.</source><volume>132</volume><year>2013</year><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">23456091</pub-id></element-citation></ref><ref id="bib0132"><element-citation publication-type="journal" id="sbref0129"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Z.T.</given-names></name><name><surname>Zou</surname><given-names>J.W.</given-names></name></person-group><article-title>Triptolide as an alternative to IVIG therapy for Kawasaki disease in a mouse model</article-title><source>Balk. Med. J.</source><volume>30</volume><year>2013</year><fpage>225</fpage><lpage>228</lpage></element-citation></ref><ref id="bib0133"><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Peng</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Liao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name></person-group><article-title>Single-nucleotide polymorphism rs2290692 in the 3&#x02032;UTR of ITPKC associated with susceptibility to Kawasaki disease in a Han Chinese population</article-title><source>Pediatr. Cardiol.</source><volume>33</volume><year>2012</year><fpage>1046</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">22361738</pub-id></element-citation></ref><ref id="bib0134"><element-citation publication-type="journal" id="sbref0131"><person-group person-group-type="author"><name><surname>Zeft</surname><given-names>A.S.</given-names></name><name><surname>Burns</surname><given-names>J.C.</given-names></name><name><surname>Yeung</surname><given-names>R.S.</given-names></name><name><surname>McCrindle</surname><given-names>B.W.</given-names></name><name><surname>Newburger</surname><given-names>J.W.</given-names></name><name><surname>Dominguez</surname><given-names>S.R.</given-names></name><name><surname>Anderson</surname><given-names>M.S.</given-names></name><name><surname>Arrington</surname><given-names>C.</given-names></name><name><surname>Shulman</surname><given-names>S.T.</given-names></name><name><surname>Yoon</surname><given-names>J.</given-names></name><name><surname>Tewelde</surname><given-names>H.</given-names></name><name><surname>Mix</surname><given-names>C.</given-names></name><name><surname>Pope</surname><given-names>C.A.</given-names></name></person-group><article-title>Kawasaki disease and exposure to fine particulate air pollution</article-title><source>J. Pediatr.</source><volume>177</volume><year>2016</year><comment>179-+</comment></element-citation></ref><ref id="bib0135"><element-citation publication-type="journal" id="sbref0132"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>X.-j.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Effects of Tanshinone &#x02161;_A for adjuvant treatment of Kawasaki disease</article-title><source>J. Appl. Clin. Pediatr.</source><volume>21</volume><year>2011</year></element-citation></ref><ref id="bib0136"><element-citation publication-type="journal" id="sbref0133"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>W.X.</given-names></name><name><surname>Xu</surname><given-names>F.Q.</given-names></name></person-group><article-title>Protective effects of Xiongshao Capsule on anti-inflammatory function of high-density lipoprotein in an atherosclerosis rabbit model</article-title><source>Chin. J. Integr. Med.</source><volume>23</volume><year>2017</year><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">26453564</pub-id></element-citation></ref><ref id="bib0137"><element-citation publication-type="journal" id="sbref0134"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H.M.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>X.Y.</given-names></name><name><surname>Cheng</surname><given-names>S.M.</given-names></name><name><surname>Huang</surname><given-names>M.F.</given-names></name><name><surname>Yue</surname><given-names>H.Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>A.P.</given-names></name><name><surname>Liu</surname><given-names>D.Y.</given-names></name></person-group><article-title>Curcumin suppressed activation of dendritic cells via JAK/STAT/SOCS signal in mice with experimental colitis</article-title><source>Front. Pharmacol.</source><volume>7</volume><year>2016</year></element-citation></ref></ref-list><ack id="ack0001"><title>Acknowledgments</title><p>This work was supported by grants from the <funding-source id="gs0001">Macao Science and Technology Development Fund</funding-source> (Project Code: 0060/2018/A2 and 0036/2018/AFJ), and <funding-source id="gs0002">Foshan Medicine Dengfeng Project</funding-source> (2019-2021) .</p></ack></back></article>